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substrates ranging from amorphous aggregates to amyloid fibers. A mechanistic understanding of Hsp104's
substrate remodeling activities remains poorly defined. The hexamer undergoes large conformational changes
upon ATP hydrolysis, but the details of these changes and how they are coupled to substrate remodeling are
unresolved. The goals of this thesis were to elucidate low and high-resolution structural information about the
Hsp104 hexamer and to discover new details of the mechanism of substrate remodeling.
We used the in solution structural techniques small angle x-ray scattering and synchrotron x-ray footprinting,
complemented by several biochemical assays, to elucidate novel roles for several Hsp104 domains, and to
develop a comprehensive model for how the Hsp104 hexamer engages substrate and unleashes its remodeling
capabilities. We discovered that the N-terminal domain (NTD) is involved in substrate binding, productive
interactions with Hsp70, and an interface with nucleotide binding domain 1 (NBD1) and the middle domain
(MD). We discovered a loop in NBD1 that may engage substrate in the ADP bound state to prevent
premature substrate release, identified the region of the MD (helix 2) responsible and the mechanism of signal
transmission between NBD1 and NBD2, and confirmed the validity of a hexameric model of the NBD2
domain.
Hsp104 engages substrate in the ATP-bound state. We have found that in this state Hsp104 displays an
increase in rigidity, which we propose as a pre-payment of the entropic cost of substrate binding. Initial
substrate engagement in the NTD and NBD1, as well as Hsp70 interactions at the NTD:NBD1:MD interface,
serve to `prime the pump'. These interactions result in large conformational changes of the MD, specifically in
helix 2, which spans the entirety of the domain. These conformational changes increase MD dynamics,
partially releasing MD:NBD2 contacts, and allow signal transmission between NBD1 and NBD2. As NBD2
responds to these signals, a positive feedback loop is created. Further nucleotide binding in NBD2 stimulates
ATP hydrolysis in NBD1, and substrate is remodeled by iterative binding events and peristaltic motions of the
Hsp104 hexamer channel.
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ABSTRACT 
 
STRUCTURAL AND MECHANISTIC INSIGHTS INTO THE YEAST DISAGGREGASE HSP104 
Elizabeth A Sweeny 
Dr. James Shorter 
Hsp104 is a hexameric, AAA+ disaggregase from yeast, which couples ATP hydrolysis to 
remodeling diverse substrates ranging from amorphous aggregates to amyloid fibers. A 
mechanistic understanding of Hsp104’s substrate remodeling activities remains poorly defined. 
The hexamer undergoes large conformational changes upon ATP hydrolysis, but the details of 
these changes and how they are coupled to substrate remodeling are unresolved. The goals of 
this thesis were to elucidate low and high-resolution structural information about the Hsp104 
hexamer and to discover new details of the mechanism of substrate remodeling. 
We used the in solution structural techniques small angle x-ray scattering and 
synchrotron x-ray footprinting, complemented by several biochemical assays, to elucidate novel 
roles for several Hsp104 domains, and to develop a comprehensive model for how the Hsp104 
hexamer engages substrate and unleashes its remodeling capabilities. We discovered that the N-
terminal domain (NTD) is involved in substrate binding, productive interactions with Hsp70, and 
an interface with nucleotide binding domain 1 (NBD1) and the middle domain (MD). We 
discovered a loop in NBD1 that may engage substrate in the ADP bound state to prevent 
premature substrate release, identified the region of the MD (helix 2) responsible and the 
mechanism of signal transmission between NBD1 and NBD2, and confirmed the validity of a 
hexameric model of the NBD2 domain. 
Hsp104 engages substrate in the ATP-bound state. We have found that in this state 
Hsp104 displays an increase in rigidity, which we propose as a pre-payment of the entropic cost 
of substrate binding. Initial substrate engagement in the NTD and NBD1, as well as Hsp70 
interactions at the NTD:NBD1:MD interface, serve to ‘prime the pump’. These interactions result 
in large conformational changes of the MD, specifically in helix 2, which spans the entirety of the 
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domain. These conformational changes increase MD dynamics, partially releasing MD:NBD2 
contacts, and allow signal transmission between NBD1 and NBD2. As NBD2 responds to these 
signals, a positive feedback loop is created. Further nucleotide binding in NBD2 stimulates ATP 
hydrolysis in NBD1, and substrate is remodeled by iterative binding events and peristaltic motions 
of the Hsp104 hexamer channel.  
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Chapter 1: Background and significance 
	  
1.1 Protein folding  
Proper cellular function and viability is dependent upon proteins being able to efficiently 
fold into their functional, native states [1]. Not only does an inability to correctly fold prevent 
proteins from performing their cellular functions [2-4], but unfolding and misfolding of proteins can 
lead to protein aggregation, a state associated with numerous human diseases [1, 2, 4-7]. 
Anfinsen’s seminal work showed that a protein’s amino acid sequence contains all of the 
information necessary for it to adopt its functional, three-dimensional shape[8] – but it turns out 
that this is only part of an even more interesting story. More recent work has shown that proteins 
are capable of accessing a number of different folds and oligomeric states, and emerging work 
indicates that this is unlikely to be an evolutionary error [9, 10]. Not only do these different states 
represent intermediates along multiple parallel folding pathways, but also the conformational 
diversity of natively folded proteins [11, 12]. Small changes in energy can result in large 
conformational changes [12] and these fluctuations allow proteins to sample a huge variety of 
states, resulting in a dynamic ensemble of protein conformations at any given time [11, 12]. 
In addition to thermal fluctuations, which allow proteins to explore small changes in 
conformation, some proteins can access a number of different conformational states based on 
chemical and protein partners, and environmental conditions [13-18]. Indeed, a growing number 
of proteins have been found to contain regions or domains that do not even fold into three-
dimensional structures under normal physiological conditions [15, 19]. These intrinsically 
disordered proteins may adopt structure upon posttranslational modifications [13-15], ligand 
binding [14-16] (often DNA or RNA), protein-protein interactions [15, 16], chaperone binding [17, 
20], or environmental changes within the cell [18]. Many of these proteins are involved in crucial 
cell regulatory pathways [15, 19], and control over their temporal and spatial activity along with 
targeted degradation is critical for cell health [6]. The realization that there are ongoing protein 
transitions between partially and fully folded states, monomeric and oligomeric states, and even 
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the assembly and disassembly of large heterologous protein complexes, reveals that nature has 
exploited the ability to control protein folding to regulate cellular functions.  
The conformational state of proteins in the cell is, by necessity, tightly regulated. 
Controlling the conformational state of the proteome in the crowded environment of the cell, 300-
400mg/mL [21], is not trivial. To minimize the presence of incorrectly folded proteins, the cell 
contains chemical and molecular chaperones to help nascent and denatured polypeptides fold 
[22, 23], protein-remodeling factors to rescue aggregated proteins [24, 25], and protein 
degradation systems to clear the cell of proteins resistant to re-folding efforts [26, 27]. In addition 
to these safeguards there are a number of factors that regulate controlled conformational shifts, 
into stress granules [28, 29], functional amyloids and prions [20, 30-34], and other protein 
complexes [9, 10] that may either activate, inactivate, or modify the activity of a given protein [9, 
10, 20, 28-34]. When these transitions are improperly controlled, pathogenesis may occur [1].  
 
1.2 Aggregation, amyloids and prions 
There are two types of protein aggregates, disordered and ordered. Which type of 
aggregation occurs is a function of protein sequence and environment, and a vast number of 
proteins appear capable of accessing either aggregated state [35, 36]. Amorphous aggregates 
are largely unstructured with little long-range order [35]. These aggregates can be induced in vitro 
by exposure to heat and high protein concentrations and are soluble in chemical denaturants 
such as SDS [35]. Amorphous aggregates have been found associated with human diseases 
such as ALS [37, 38], multisystem proteinopathy [37], cancer [39], and cystic fibrosis [40].  
Amyloid aggregates display stable long-range order comprised of characteristic cross-β 
fibrils, in which the β-strands run perpendicular to the fiber axis [41-44]. The ends of the fibers act 
as templates seeding the conformational change of natively folded versions of the protein into the 
amyloid form [45]. Amyloid displays a number of physical characteristics such as a unique x-ray 
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diffraction pattern resulting from the uniform, repeating fiber structure [41, 42], an ability to bind 
certain dyes and change their spectroscopic qualities [46-48] (termed ‘amyloid binding dyes’ such 
as Thioflavin T and congo red), a fibrillar morphology when viewed using electron microscopy 
[48], and a resistance to solubilization by denaturants such as SDS [49, 50], heat [51] and even 
proteases [52]. The term prion simply refers to infectious amyloid [7], meaning that the 
conformational state can be passed to different individuals – such as mother to daughter 
inheritance of yeast prions [53] – or between species – such as cow to human transmission in 
bovine spongiform encephalopathy [54], or mad cow disease. Amyloids and prions are often 
associated with human disease; cardiac amyloids, cardiomyopathy, cerebral amyloid angiopathy, 
Alzheimer’s disease, Parkinson’s disease, type II diabetes, prion diseases and more [55, 56]. 
These diseases can stem from a number of factors including genetic mutation, environmental 
stresses, or simply age [55, 56]. However, more recent work has revealed that amyloids and 
prions are not always detrimental; in a growing number of cases they have been found to play 
important roles in a number of organisms from bacteria to humans [20, 30-34]. Once again we 
find that transitions from one conformational state to another are an important facet of natural 
protein function, it is only when control over these transitions is lost that severe, sometime lethal, 
complications develop [7].  
The formation of amyloid occurs through a series of oligomeric species and eventual 
nucleation of fibril growth [57] (Figure 1). A growing number of proteins have been found to be 
capable of accessing the amyloid form and it has even been suggested that under the right 
circumstances all proteins could adopt the amyloid conformation [36]. Generally, there is either a 
region, or domain, which is largely unstructured [58], or there is an environmental shift that 
causes some form of unfolding [59]. Sampling of conformational space by the unfolded regions 
leads to the build-up of oligomeric species [57]. Initially, these oligomeric species are soluble, but 
at some point there is a transition to insoluble oligomers with amyloid characteristics [57, 58]. 
There is evidence that in human disease some of these oligomers are responsible for cellular 
toxicity [60-62] and therefore there has been an interest in characterizing the structure and other 
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properties of these oligomers and understanding what controls the transition from one to another. 
The ability to develop antibodies that recognize oligomeric, but not monomeric or fibrillar 
conformations of a variety of amyloid forming proteins indicates that there are common structural 
elements within the amyloidogenic oligomers [63]. When spontaneous amyloid formation is 
tracked over time (i.e. in the absence of preformed amyloid), the result is a sigmoidal curve 
(Figure 1); the interplay between different oligomeric species represents a lag phase, during 
which time there is little to no amyloid characteristic [57]. During this slow, thermodynamically 
unfavorable phase there is a diverse range of oligomeric structures sampled [57]. Details such as 
temperature, buffer conditions and the presence of mutated proteins can have dramatic influence 
over the nature of these oligomeric species [57]. The next phase of amyloid formation progresses 
once nucleation occurs, i.e., amyloidogenic oligomers capable of seeding fiber formation have 
evolved. During this polymerization, or exponential phase, the curve displays a rapid increase of 
amyloid structure as the nucleated fibers grow from each end (Figure 1). These fiber ends act as 
templates, converting soluble versions of the protein into the amyloid state [64]. The lag phase 
can be shortened or even skipped altogether if amyloidogenic seed is added to the soluble 
species [64]. Interestingly, there is evidence showing that under certain circumstances, cross-
seeding may even be possible [65-68], i.e., seeding amyloid formation of protein X by 
amyloidogenic versions of protein Y. This behavior may have important implications for the 
progression of a number of human diseases [65]. Eventually, fiber growth slows and the curve 
plateaus; at this point an equilibrium has been reached between the amyloid and soluble species 
[57]. Monomeric versions of the protein come off and onto the fiber ends, but as a whole the 
large, fibrous structure remains highly stable [57].  
Though the amyloid, or prion state of proteins has been largely associated with 
devastating human diseases, it is not always an aberrant state [20, 30-34]. In yeast, prions act as 
self-propagating, protein-based heritable elements; they display non-Mendelian segregation in 
crosses [69, 70], can be cytoduced [71, 72], and reversibly cured [71, 73]. Yeast prions confer 
diverse and often beneficial phenotypes to the cells that harbor them [74]. These changes can be  
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due to partial loss of function, such as seen with [PSI+] [70, 75] and [URE3] [71], or the gain of a 
novel function such as with [PIN+] [68], [ISP+] [76] and [MOD+] [77]. One of the best characterized 
yeast prions, [PSI+], is comprised of the translation termination factor, Sup35 [78, 79]. The 
depletion of soluble Sup35 upon prionogenesis results in the partial read-through of stop codons, 
suppression of nonsense mutations [75] and access to novel gene products, some of which are 
advantageous [53, 80].  
 Initially there were a limited number of yeast prions described, namely [PSI+] [20, 81, 82], 
[URE3] [71, 83] and [RNQ+] [30, 84], and it was proposed that they may have been a by-product 
of the yeast being cultivated in a laboratory environment [85]. However, more recently prions 
have been found in a variety of wild-yeast strains, indicating that it is not a laboratory artifact [85]. 
Further, the discovery of at least 24 additional yeast proteins that appear to have a prion-forming 
domain [86] indicates that use of the prion conformation may be a common mechanism in yeast. 
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Prion-forming domains (PrDs) have been identified as necessary and sufficient to facilitate the 
transition between the soluble and prion form [84, 87-89]. PrDs are largely unfolded and are often 
rich in polar uncharged residues [90]. They are independent of functional domains, and can be 
transferred to other proteins to induce the prion state [84, 88], while deletion of the PrD leads to 
an inability to form prions [84, 88]. Interestingly, when an algorithm designed to identify novel 
prion domains was applied to the human genome, a number of the identified proteins have been 
found associated with devastating neurodegenerative diseases [91]. Many of the identified 
domains are found in RNA-binding proteins, which are involved in the development and dynamics 
of beneficial, aggregation-like structures such as stress granules [92]. This then returns us to the 
theme of controlled protein aggregation playing a crucial role in normal cellular function. Tight 
regulation over conformational transitions is essential, indeed, even in the case of [PSI+], a 
potentially beneficial prion state, excessive amounts of aggregated Sup35 results in toxicity [93].  
Understanding how yeast regulate their well-characterized prion states has broad 
implications for understanding how higher eukaryotes may regulate the aggregation state of their 
proteomes, as well as allow for the targeted design of novel therapeutics to use against aberrant 
protein aggregation in human disease. Yeast employ both environmental signals and modulation 
of chaperones expression levels to control the prion state of its proteins [77, 94, 95]. Certain 
environmental stresses such as the presence of antifungals for [MOD+] [77], or ethanol for 
[MOT3+] [94], can induce the prion state of the Mod5 and Mot3 proteins respectively. The network 
of chaperones that play a role in prionogenesis and curing is more complex, and is best 
understood for the canonical prion protein, Sup35. Central to the regulation of prion state is the 
AAA+ protein Hsp104, however, a number of other chaperones have been found to play 
important roles in vivo, namely the Hsp70 system, which includes Hsp40 chaperones as well as 
Hsp70 nucleotide exchange factors (NEFs) [95]. 
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1.3 Hsp104 function in yeast 
Hsp104 is a hexameric, Hsp100 AAA+ (ATPases Associated with various cellular 
Activities) [96, 97] disaggregase [98]. AAA+ proteins have been described as molecular machines 
[99], coupling ATP hydrolysis to protein degradation [99, 100], remodeling and dismantling of 
macromolecular complexes [97], translocation of proteins and nucleic acids [99, 101], as well as 
resolubilization of aggregates [96, 102]. Hsp104 appears to be involved in all things aggregate in 
the yeast cell; from amorphous aggregates formed after heat shock, to the regulation of prion 
proteins, to control over the segregation of carbonylated, aggregated proteins in order to control 
aging and cell death [103-105]. 
Hsp104 was originally discovered as a gene required for induced thermotolerance in 
Saccharomyces cerevisiae [106]. When yeast cells were pre-incubated at 37°C for 30 minutes 
prior to heat shock at 50°C for 20 minutes, the cells containing a wild-type version of the Hsp104 
gene displayed a 100- to 1000-fold increase in survival compared to yeast lacking the Hsp104 
gene[106]. After the initial discovery of its critical role in thermotolerance Hsp104 was found to 
confer tolerance to ethanol, arsenite, and prolonged exposure to the cold as well [107]. Hsp104 is 
a member of the ClpA/ClpB protein family [108]. Unlike Hsp70 chaperones, which can prevent 
aggregation of unfolded polypeptides [22], or ClpA, which promotes proteolysis of proteins [109], 
it was shown that Hsp104 protects cells from stress, including heat shock, through the 
resolubilization and reactivation of insoluble protein aggregates [110, 111], generally once the 
stress was removed. 
It was subsequently discovered that Hsp104 plays a central role in the regulation of yeast 
prions [112]. Hsp104 is necessary for the propagation of all known naturally occurring amyloid-
based yeast prions including [PSI+] [20, 81, 82], [URE3] [83] and [RNQ+] [30, 84], and 
demonstrates concentration dependent effects on the yeast prions [PSI+] [82] and [MOD+] [77]. 
Prionogenesis of Sup35 and resulting mother-to-daughter transmission results in the [PSI+] [20, 
81, 82] phenotype. Prionogenesis can either be promoted, and inheritance maintained, or it can 
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be inhibited and even cured, i.e., the prion phenotype lost [82]. In vivo, Hsp104 deletion or over-
expression eliminates [PSI+] [82]. Pure protein biochemistry has revealed that low concentrations 
of Hsp104 catalyze Sup35 prionogenesis by nucleating fiber assembly[20, 81], and by severing 
fibers to increase the number of growing fiber ends[20, 81]. By contrast, at high concentrations 
Hsp104 couples ATP hydrolysis to the disassembly of both Sup35 fibers and oligomers into non-
infectious conformers[20, 81, 113]. In vivo, and in vitro, the concentration dependent activity is 
tuned by the presence of Hsp70:Hsp40 pairs as well as NEFs [114].  
A number of papers have dissected the role of various Hsp70:Hsp40 pairs as well as 
NEFs in the prionogenesis of Sup35 [95]. Hsp70 chaperones are ATPases that bind and release 
substrates that contain large regions of unfolded and non-natively folded polypeptide [22]. In the 
ADP bound state Hsp70 has a high affinity for substrate, and in the ATP bound state the affinity is 
much lower [22]. This difference in affinity results in rounds of substrate binding and release, 
which prevents interactions with other unfolded proteins that could lead to aggregation, as well as 
giving the substrates the chance to re-fold into the native state upon their release [22]. However, 
the basal rate of ATP hydrolysis for Hsp70 is very low, and therefore they require the activity of 
Hsp40 proteins, which contains ATPase stimulating J-domains [22]. In addition to Hsp40, there 
are a number of NEFs, which stimulate the exchange of ADP for ATP [22]. There are two Hsp70 
subfamilies that have been shown to affect [PSI+], Ssa, whose four members are found 
throughout the cytoplasm [115] and Ssb, whose two members are mostly associated with the 
ribosome [116]. While Ssb is always a [PSI+] antagonist [117-119], Ssa has been shown to either 
promote [117, 120-123] or antagonize [118, 121, 124] [PSI+] based on protein partners and 
environmental factors (Figure 2).  
Ssa1 mainly collaborates with the Hsp40 proteins Ydj1 and Sis1 [125] while Ssb1 
requires a heterodimer of Zuo1, an Hsp40, and Ssz1, an atypical Hsp70 [126]. Fes1 and Sse1 
are NEFs that are able to facilitate nucleotide exchange for both Ssa1 and Ssb1 [127-130]. The 
Ssb1:Zuo1:Ssz1 complex, generally associated with the ribosome, is a potent antagonist of  
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Sup35 prionogenesis [114]. Although unable to rapidly disassemble preformed Sup35 prions 
[114], a number of Hsp70:Hsp40 pairs appear to bind both Sup35 oligomers and fibers, 
disassembling soluble oligomers [114] and blocking nucleation and seeding events [114]. These 
activities allow for overexpression of Hsp70:Hsp40 to cure certain [PSI+] phenotypes [118, 124]. 
The Hsp40 proteins Sis1 and Ydj1 preferentially interact with the Sup35 oligomers and fibers 
rather than the monomers and promote Ssa1 and Ssb1 binding [114]. The NEF Sse1 was found 
to directly stimulate prionogenesis of the prion domain of Sup35 [123], while Fes1 had no effect 
[114]. Though Fes1 had no direct effect on Sup35 prionogenesis, it was found to diminish the 
inhibitory effects of Hsp70:Hsp40 [114]. Fundamental to the balance of this complex chaperone 
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network is the protein Hsp104 [95]. Based on its expression levels and collaboration with the 
previously described Hsp70 system, it is the main determinant of prion state (Figure 2). 
 The prion stimulating activity at low Hsp104 concentrations was found to be capable of 
overriding the inhibitory activities of Hsp70:Sis1 pairs, but not Hsp70:Ydj1 pairs [114]. 
Additionally, ex vivo Sup35 fibers contain a large amount of Ssa1/2; ~one Ssa1 for every two 
Sup35 molecules, as well as smaller amounts of Ssb1, Ydj1 and Sis1 [131]. Incorporation of 
Hsp70 and Hsp40 into the Sup35 fibers makes them better substrates for remodeling by high 
concentrations of Hsp104 [114]. Though in vivo there appears to be a delicately balanced 
interplay between Hsp104, Hsp70, Hsp40 and NEFs, in vitro experiments have demonstrated that 
Hsp104 displays robust activity promoting, inhibiting or remodeling Sup35 fibers on its own in a 
concentration dependent manner [20, 81, 114]. Indeed, it has even been shown that Hsp104 has 
the ability to remodel amyloid forms of a number of human proteins involved in disease [132], a 
feat that its bacterial homologue, ClpB, is unable to achieve [132]. 
More recently Hsp104’s role in aging was revealed [104, 105]. In the budding yeast 
Saccharomyces cerevisiae, oxidatively damaged, aggregated proteins are retained in the mother 
cell in an Hsp104-dependent manner [104, 105]. Disruption of this asymmetric inheritance of 
aggregates results in accelerated aging of the progeny [104]. Interestingly, in the fission yeast 
Schizosaccharomyces pombe aging does not occur under normal conditions, however, after the 
yeast is subjected to stress some of the cells begin to age and become more likely to die [133]. 
This increased chance of death is due to the asymmetric inheritance of large, Hsp104-associated 
aggregates formed in response to stress [133]. By forming one large aggregate which segregates 
asymmetrically to only one cell, the yeast are able to sacrifice one cell in return for the health of 
the others.  
Overall, the activity of Hsp104 appears to be focused on the control of the aggregation 
state of a number of proteins as well as the spatial localization of aggregates [103, 134]. The 
questions then become almost endless: How does Hsp104 carry out these activities? Does it 
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employ the same mechanism for all of its diverse substrates? Can it sense differences in stability 
between a disordered and amyloid aggregate? When does its function shift from remodeling, to 
sequestration of aggregates? Is remodeling coupled to sequestration? To understand and begin 
to answer these questions we need to examine details about the structure and possible 
mechanisms of the Hsp104 hexamer. 
 
1.4 Hsp104 mechanism and structure 
1.4.1 Overview 
A mechanistic understanding of Hsp104’s substrate remodeling activities remains poorly 
defined [135]. An Hsp104 monomer is 908 residues and 102kD; the fully assembled hexamer is a 
large, hollow, barrel shaped molecule [102, 136] with 12 sites capable of ATP binding and 
hydrolysis. The hexamer undergoes large conformational changes upon ATP hydrolysis [137, 
138], but the details of these changes as well as how they are coupled to substrate remodeling is 
unclear. There are no high-resolution structures, and most mutagenesis analyses have relied on 
random mutagenesis, or focused on a few highly conserved residues such as those found in the 
nucleotide binding pockets [138]. Hsp104 is comprised of five domains, the N-terminal domain 
(NTD), two nucleotide-binding domains (NBD1 and NBD2), a coiled-coil middle domain (MD) 
inserted within NBD1, and a unique C-terminal extension [138]. The hexameric structure of 
Hsp104 remains unresolved. In fact, two radically distinct models have been advanced [135]. 
Both are based on cryo-EM reconstructions with rigid body fit domains from the crystal structure 
of the Thermus thermophilus homolog, tClpB [102]. Unfortunately, tClpB was resolved as a spiral 
of 3 ClpB monomers with distinct conformations, rather than the functional, hexameric state [102]. 
Using assumptions based on other AAA+ proteins and poorly documented cryo-EM 
reconstructions of chemically fixed tClpB, an initial hexameric structure with an external 
placement of the coiled-coil was proposed [102]. However, this structure was incompatible with 
the dimensions of Hsp104 hexamers observed by another cryo-EM study [136]. This led to a 
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second model with the coiled-coil domain intercalated between the two nucleotide-binding 
domains [136]. However, this new model did not preserve the typical AAA+ nucleotide binding 
sites, and the debate over the hexameric structure continues [135]. The stability of the hexamer is 
affected by the presence of nucleotide [139] and salt concentration [140]. Nucleotide binding 
stabilizes the hexamer, while high salt concentrations favor the monomer and smaller oligomers 
such as dimers and trimers. The domains appear to cooperate in a highly tuned manner in order 
to remodel diverse substrates and substrate structures [132]. Each domain plays specific roles, 
and allosterically communicates with adjacent domains and subunits [138]. However, the details 
of intra- and inter-protomer communication, and precisely what role(s) the individual domains play 
in substrate remodeling are not fully resolved.  
 
1.4.2 The N-terminal Domain (NTD) 
Crystal structures of the N-terminal domains of the bacterial Hsp100 proteins ClpA [141], 
ClpB [102, 142], and ClpC [143] have been solved. The NTDs are highly structurally conserved; 
they are very stable globular domains [141-144] made up of two imperfect repeats of four helical 
bundles [141-143] and are connected to the adjacent nucleotide-binding domain by a highly 
mobile linker [102, 145-147]. In the bacterial disaggregase ClpB, Hsp104’s orthologue, the NTD 
appears to be involved in substrate binding [102, 142, 148-151], casein-stimulated ATPase 
activity [148], and its mobility via the NTD-NBD1 linker is necessary for efficient translocation and 
disaggregation of substrate [152, 153].  
In contrast to the bacterial Hsp100 proteins, the function of the Hsp104 N-terminal 
domain has been poorly explored. In vivo, deletion or specific point mutations (e.g. T160M) within 
the N-terminal domain has little effect on thermotolerance or prion propagation [154]. Therefore, 
Hsp104 can still dissolve heat-denatured aggregates and fragment prions. Yet, over-expression 
of these mutants fails to cure [PSI+] [154]. This suggests that Hsp104’s ability to eliminate amyloid 
conformers is selectively perturbed and that there may be a fundamental difference in how 
13	  
	  
amorphous and amyloid substrates are remodeled. Indeed, a recent paper found that 
cooperativity of the subunits was dispensable for reactivation of amorphous aggregates, while 
global cooperativity was needed for remodeling of amyloid substrates [132]. This indicates that 
the NTD may be essential for global cooperativity. In addition to this possibility, the NTD of 
Hsp104 may participate in substrate binding and interactions with adapter proteins such as 
Hsp70, although the role(s) of the Hsp104 NTD remains unknown. 
 
1.4.3 Nucleotide Binding Domains (NBD1 and NBD2) 
Hsp104 contains two canonical AAA+ domains, designated NBD1 and NBD2. Each NBD 
contains highly conserved AAA+ motifs but belong to different AAA+ clades (subgroups) [155]. 
These clades are defined by the insertion of specific secondary structure elements within the core 
AAA+ fold, and have specific functional consequences [155, 156]. Since the NBDs belong to 
different clades, (clade 3 for NBD1 and clade 5 for NBD2) it has been proposed that the protein 
arose from a gene fusion event rather than a gene duplication event [155]. Each domain is able to 
bind and hydrolyze ATP, but they have very different catalytic properties [140]. By fitting the 
steady-state kinetics of ATP hydrolysis to two independent allosteric sites, and following up with 
mutational analyses, the general properties of the two NBDs were determined [140]. NBD1 
contains a low affinity, high turnover site and NBD2 a high affinity, low turnover site [140]. Both 
domains display positive cooperativity, and a high degree of allosteric communication between 
the two, e.g., hydrolysis in NBD1 depends upon the nucleotide state of NBD2 [140].  
The nucleotide binding domains of AAA+ proteins are highly structurally conserved, 
consisting of a large, α/β subdomain and a small α-helical subdomain [156]. Features that define 
these domains include regions involved in ATP binding and hydrolysis, namely the Walker A and 
Walker B motifs, the arginine finger, sensor-1 and sensor-2 residues (Figure 3), as well as pore 
loops that couple conformational changes of the AAA+ protein due to ATP hydrolysis to substrate  
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remodeling [155]. In addition to the conserved AAA+ motifs, NBD2 was discovered to contain a 
nuclear localization signal (NLS) [157]. 
The P-loop, or Walker A motif, is common in a number of ATPases and GTPases and 
has the consensus sequence GXXXXGKT/S [158, 159]. The Walker A residues, particularly the 
highly conserved lysine, are involved in interactions with the phosphates of the bound nucleotide 
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[155] (Figure 3). Indeed, the lysine residues K218 in NBD1 and K620 in NBD2 of Hsp104 are 
essential for nucleotide binding [160]. By separately mutating conserved Walker A residues in 
either NBD1 (G217V or K218T) or NBD2 (G619V or K620T), it was revealed that NBD1 
contributes the majority of the ATPase activity, while NBD2 is responsible for nucleotide-induced 
hexamerization [160]. The Walker B motif has the consensus sequence hhhhDE [158], where h 
represents a hydrophobic residue. The aspartate residue can coordinate Mg2+ while the 
glutamate is thought to activate the attacking water in order to facilitate ATP hydrolysis [156]. In 
Hsp104, as well as many other Hsp100 proteins, mutation of the Walker B glutamate residues, 
E285 in NBD1 and E687 in NBD2, does not disrupt nucleotide binding but does inhibit hydrolysis 
(Figure 3). An interesting consequence of this is that since most AAA+ proteins, including 
Hsp104, engage substrate in the ATP-bound state, double Walker B mutants (E285Q/A:E687Q/A 
in Hsp104) can be used as substrate ‘traps’ [161]. This allows for a number of interesting 
biochemical investigations.  
The sensor-1 and sensor-2 motifs can participate in various activities including ATP 
binding, hydrolysis, discriminating between ADP and ATP, and the propagation of conformational 
changes upon hydrolysis [162]. The sensor-1 residue is found in a structurally conserved region 
called the secondary region of homology (SRH) [163]. It is a polar residue, generally Asn or Thr, 
which interacts with regions of the Walker B motif as well as the γ-phosphate of the bound ATP 
molecule [156]. Mutation of these conserved residues in Hsp104, T317 in NBD1 and N728 in 
NBD2, reduces the ATPase rate but does not affect nucleotide binding [140]. Although both 
sensor-1 mutants display a loss-of-function phenotype in vivo, the NBD2 mutant N728A is active 
in vitro in the presence of ATP and the absence of Hsp70:Hsp40, a condition in which the wild-
type protein is not active [113]. Why exactly this would be is unclear and underscores how hard it 
is to get a comprehensive picture of mechanism in a protein as large and complex as Hsp104. 
The sensor-2 motif, GAR, is located in the small α-helical subdomain and the conserved Arg 
interacts with the γ-phosphate of the bound ATP [163]. In Hsp104 NBD1 does not appear to have 
16	  
	  
a sensor-2 motif [102]. In NBD2 mutation of the conserved Arg, R826, results in an equal 
decrease in binding to both ADP and ATP, as well as a decrease in ATP hydrolysis in NBD1 
[164]. At the far end of the SRH from sensor-1 is the arginine finger, which completes the ATP-
binding pocket (Figure 3). AAA+ proteins are oligomeric and the nucleotide-binding pocket is 
located at the subunit:subunit interface [155]. An essential component of the catalytic site is the 
arginine finger, which reaches from one protomer into the active site of its neighbor, contacting 
the nucleotide [165]. In Hsp104 the arginine fingers are R334 in NBD1 and R765 in NBD2 and 
mutation of these conserved arginines results in a loss of ATPase activity. A schematic of a 
typical AAA+ catalytic site is shown in Figure 3 with AAA+ features based on the pdb 3glf [166]. 
The pore loops, or substrate binding loops, have the general consensus sequence YVG, 
and couple the large conformational changes that take place during ATP hydrolysis to the 
remodeling of substrate [167-169]. These conserved loops are on the interior of the axial channel, 
which runs the length of the hexamer N-to C-terminally [102, 136] and facilitate partial and/or full 
translocation of substrate through the channel [109, 167, 168, 170]. In Hsp104 the NBD1 
substrate-binding loop is 256-KYKG-259, and in NBD2 the more typical 661-GYVG-664; the 
highly conserved tyrosine residues, Y257 and Y662 are the most essential for substrate binding 
[167]. In vivo, Y257A displays a reduction in survival after heat shock of only ~10-fold, while 
Y662A fared only slightly better than having no Hsp104 at all [167]. This implies that Y662 is the 
more crucial residue, and that there may be additional substrate binding motifs in NBD1 and the 
NTD. Fluorescence studies showed that nucleotide binding in NBD2 determines the position of 
residue 662 [167], which supports the idea that conformational changes due to ATP hydrolysis 
are transmitted through the pore loop to the substrate.  
 
1.4.4 Middle domain (MD) 
Hsp104 and its bacterial homologue ClpB contain a ~85Å long coiled-coil middle domain 
(MD) inserted into the small α-helical subdomain of NBD1 [102]. In the two hexameric models 
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proposed for Hsp104 and ClpB, the position of the middle domain is the most highly contested. In 
one model, the domain is intercalated between NBD1 and NBD2 [136, 137] while in the other it 
projects out into solution [171]. The MD consists of four helices that make up an anti-parallel, 
broken coiled-coil [102]. Helix 1 and half of helix two are designated motif 1, with the second half 
of helix 2 along with helices 3 and 4 designated motif 2 (Figure 4). Helix 3 appears to undergo 
conformational changes in response to nucleotide, possibly transitioning between loop and helix 
[102, 172].  
The MD is essential for disaggregation activity [145, 173] and is the site of interaction 
with Hsp70 [172-175]. The MD has been shown to interact with NBD1 in an auto-inhibitory 
fashion, repressing activity of the hexamer [172, 175-177]. Hsp70 binds directly to the MD, 
specifically in the region of helix 2 in motif 2 [174, 175, 178]. This interaction appears to relieve 
the autoinhibitory interactions between the MD and NBD1 [174, 175, 178]. Thus, it appears that 
the MD is a highly dynamic domain involved in regulation of the hexamer activity. Indeed, point 
mutations in the MD can lead to inactive variants with stabilized MD-NBD1 interactions [176], or 
hyperactive variants with enhanced unfolding power [176, 179]. Recent findings have begun to 
uncover the role and characteristics of the MD, however, many of the details of the placement, 
dynamics and the mechanism of MD-mediated regulation remain unresolved. 
 
1.4.5 C-terminal Domain (CTD) 
Hsp104 contains a unique C-terminal extension of ~50 residues. The region is enriched 
in acidic residues, and the last four residues are a conserved DDLD motif that allows binding to 
the chaperone Cpr7 [180], although the importance of this interaction remains unknown as 
deletion of the motif does not affect thermotolerance [180]. The CTD was initially thought to be a 
main site of substrate interaction [181], and CTD binding to lysine rich polypeptides stimulates 
ATPase activity in NBD1 via the MD [181]. However, subsequent work supported a model in 
which substrates are translocated N- to C-terminally [111, 161], which leaves poly-Lys binding at  
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the CTD of mysterious function. More recently, the CTD was shown to be essential for 
hexamerization [180, 182], and though the sequence indicates that it is highly disordered, this 
role implies that may not necessarily be the case.  
 
1.5 Research aims 
Hsp104 is a large, dynamic, multi-domain hexamer that couples large conformational 
changes due to ATP hydrolysis to applying mechanical force to myriad substrates [138]. A better 
understanding of the structure and mechanism of Hsp104 will not only allow insight into its natural 
function, but open the door for directed evolution and protein design to tailor Hsp104 to 
specifically remodel disease associated aggregates, as well as other therapeutic and research 
purposes. 
The goals of this thesis were to elucidate low and high-resolution details about the 
structure and substrate remodeling mechanism of Hsp104. First, I set out to determine the role of 
the Hsp104 NTD and to visualize large conformational changes of the hexamer using 
SAXS/WAXS in order to make and test predictions about the structure and mechanism of 
Hsp104. Specifically, we first aimed to understand why deletion of the NTD (ΔN-Hsp104) resulted 
in an inability to remodel amyloid substrates and to use our findings to understand mechanistic 
details of the wild-type hexamer. Secondly, we used an in solution technique, x-ray footprinting 
(XF), that directly probes the solvation state of the Hsp104 hexamer in the presence of different 
nucleotides. The changes in solvation allowed us to make predictions about what these 
conformational changes mean for the individual domains, the Hsp104 hexamer as a whole, and 
the mechanism of substrate remodeling. Using a variety of biochemical techniques, we tested 
these predictions and were able to elucidate novel insights into substrate binding and processing, 
interaction with Hsp70, movements of the coiled-coil middle domain, and the subunit:subunit 
interface. 
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Chapter 2: The role of the N-terminal domain (NTD) of Hsp104 
	  
2.1 NTD introduction 
The bacterial Hsp100 proteins ClpA [183] and ClpB [148] have internal start sites which 
allow for the production of truncated protein products missing the N-terminal domain (NTD). 
These natural Hsp100 truncations as well as other N-terminal truncations have been examined in 
the literature for ClpA and ClpB as well as other AAA+ proteins. The activity of these truncated 
products varies depending upon the identity and structure of the substrate [141, 144, 145, 148, 
149, 183], and the location of the truncation [141, 144, 145, 148, 183, 184]. The crystal structures 
of the NTDs of the bacterial Hsp100 proteins ClpA [141], ClpB [102, 142], and ClpC [143] have 
been solved. The NTDs are structurally conserved; they are very stable globular domains [141-
144] made up of two imperfect repeats of four helical bundles [141-143] and are connected to the 
NBD1 domain by a highly mobile linker [102, 145-147]. Strikingly, though the structure of the 
repeats differs in content, other AAA+ proteins such as mammalian p97 and NSF also have 
NTDs that contain two subdomains [185] connected to the NBD1 domain via mobile linkers [186, 
187], and the NTDs may play similar roles in activity [187-190]. 
For the bacterial Hsp100s, though the effects vary with the details of substrate and the 
location of the N terminal truncation, the NTD as well as the linker between the NTD and NBD1 
domains have been shown to play a role in a number of functions. These include regulation of 
binding and hydrolysis of ATP in the nucleotide binding domain(s) [144, 148, 183, 187], substrate 
interaction [102, 141, 142, 144, 148-151], binding to adaptor proteins [141, 143, 188-192] and 
controlling access to the central channel [136, 146, 184].  
The NTD is not directly involved in ATP hydrolysis, however, the deletion of the NTD has 
been shown to affect the behavior of the ATP-binding domains [144, 148, 183, 187]. These 
effects are not always the same and vary depending on whether the NTD to NBD1 linker is also 
removed [144, 148, 183, 187]. In ClpA, NTD deletion has been shown to decrease the ATPase 
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rate [144, 183], in ClpB, eliminate the stimulation of ATPase rate by substrate [148], and in p97 
the linker, along with the NTD-NBD1 interface has been shown to control the number of ATP 
molecules that the NBD1 domain can bind at a given time [187]. Mutations in these regions in p97 
have been linked with inclusion body myopathy with early-onset Paget disease and 
frontotemporal dementia (IBMPFD), a devastating autosomal dominant degenerative disease 
[187]. 
The region of the NTD that binds substrate is a highly-conserved hydrophobic patch that 
is exposed to solvent and lies between the two subdomain repeats [102, 141, 142, 144, 150]. 
Even p97, with its divergent NTD structure retains a hydrophobic pocket between its NTD 
subdomains [188], though it binds an adaptor protein p47 rather than substrate [188]. Near the 
hydrophobic patch are two acidic residues that have been implicated in substrate binding in ClpB 
[150], specifically involved in processing large aggregates [150]. In ClpA the corresponding 
residues are arginine and alanine, and it has been proposed that the sequence variation is 
related to differences in substrate specificity [150].  
Several AAA+ proteins require binding of adaptor proteins for proper hexamer formation 
[143, 193], determining substrate specificity [141, 191], or for stimulation of activity [24, 141, 188-
190, 193-195]. Many of these adaptor proteins interact with the NTD [141, 143, 188-190]. In the 
case of ClpC and its adaptor protein MecA and ClpA with its adaptor protein ClpS, the exact site 
of interaction is conserved [141, 143]. In fact, the only examples of non-NTD sites of adaptor 
protein interaction occur in the MD, a unique coiled-coil domain inserted within the first 
nucleotide-binding domain in Hsp104 and ClpB [172-175, 196]. ClpC has a truncated version of a 
coiled-coil middle domain [143]. Interestingly, the ClpC-MecA interaction occurs at both the NTD 
and the MD [143].  
Despite the plethora of data on bacterial Hsp100 NTDs, there is very little published 
information on the NTD of the AAA+ yeast protein Hsp104, which, like ClpA [109] and ClpB [170], 
is able to unfold and translocate substrates through its central channel [167]. Curiously, Hsp104 
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does not have a corresponding internal start site, which could imply that the NTD of Hsp104 plays 
a more crucial role in activity than NTDs of its bacterial homologues. This may be due to 
Hsp104’s unique in vivo role in regulating various yeast prions including [PSI+] [20, 81, 82], 
[URE3] [83] and [RNQ+] [30, 84]. In yeast, prions act as nonchromosomal heritable elements [30, 
53, 80], which can confer selective advantages in times of stress [53, 80]. From in vivo yeast 
studies, it has been shown that the N terminal domain of Hsp104 is not necessary for 
thermotolerance or yeast prion propagation, but is essential for curing of the yeast prion 
phenotype [PSI+] caused by Sup35 prions [154, 197]. This finding led to the hypothesis that the 
Hsp104 NTD may play an essential role in the unique ability of Hsp104 to remodel amyloid 
substrates, specifically, the ability to eliminate the infectious cross-beta structure, as opposed to 
simple fragmentation without altering the cross-beta structure [198].  
In this chapter I present data from structural and biochemical techniques to understand 
the role of the Hsp104 NTD. We wanted to understand how the NTD contributes to Hsp104 
function, and therefore illuminate new details of how Hsp104 remodels amyloid aggregates into 
non-infectious forms. This work elucidates, for the first time, the essential role of the NTD in 
cooperativity of the hexamer. Recent work in our lab revealed that the ability of the Hsp104 
hexamer to remodel amyloid substrates depends upon a high degree of plasticity and the ability 
to operate in a fully cooperative manner [132]. The following work details how deletion of the NTD 
results in a stable Hsp104 hexamer with a diminished ability to undergo productive 
conformational changes, specifically in the channel running the length of the hexamer. This 
profound alteration in conformational changes leads to defects in hexamer cooperativity. These 
defects in cooperativity then lead to deregulation of the ATPase cycle and various functional 
defects. These findings establish that the Hsp104 NTD is crucial for robust Hsp104 activity, 
necessary for the global cooperativity needed for amyloid remodeling, and explain why an internal 
start site is not found in the Hsp104 gene. The NTDs of Hsp100 proteins are often removed for 
ease of in vitro biochemical characterization. Our work implicates that this practice, at least for 
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Hsp104, could lead to drastic changes in how the hexameric assemblies function, even if activity 
remains.  
 
2.2 Results 
2.2.1 The NTD is required for inhibition of Sup35 amyloid formation in vitro 
Yeast studies have shown that the NTD of Hsp104 is required for curing the yeast prion 
phenotype [PSI+] through Hsp104 overexpression [154, 197]. The [PSI+] prion phenotype is 
caused by the translation termination factor, Sup35, forming infectious amyloid conformations [78, 
79]. Pure protein biochemistry using Sup35 has been shown to recapitulate the in vivo 
concentration dependent activity of Hsp104 on prions [20, 81]. At low concentrations Hsp104 
promotes amyloidogenesis by nucleating fiber formation as well as severing the fibers to increase 
the number of growing ends [20, 81]. Conversely, at high concentrations, Hsp104 is able to 
completely remodel the Sup35 amyloid fibers into non-infectious, soluble conformations [20, 81, 
113, 114]. We decided to test whether deletion of the NTD resulted in defects in prion remodeling 
in vitro.  
Using Sup35 as our model substrate we monitored amyloid formation over time using an 
amyloid binding dye, Thioflavin T (ThT), which increases in fluorescence when bound to amyloid 
[47]. We also used negative stain electron microscopy (EM) to visualize the reaction products. By 
adding either WT Hsp104 or a NTD truncation mutant (ΔN Hsp104), we could monitor how 
deletion of the NTD affected the ability of Hsp104 to alter the conformational state of Sup35. We 
began by testing the effect on Sup35 amyloid assembly at a concentration shown to be inhibitory, 
a ratio of Sup35 monomer to Hsp104 hexamer of 15:1 [20]. We found that while the WT Hsp104 
inhibited amyloid assembly as expected, ΔN Hsp104 enhanced fibrilization (Figure 1A). Since this 
behavior resembled what occurs at low concentrations of WT Hsp104 [20, 81], we next tested 
whether we would see inhibition of Sup35 fibrilization at higher ΔN Hsp104 concentrations. We 
found that even up to a ratio of Sup35 monomer to ΔN Hsp104 hexamer of 3:1, Sup35 amyloid  
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formation was enhanced by the ΔN Hsp104 variant (Figure 1B). Our ThT findings were confirmed 
by negative stain EM. Low concentrations of both WT and ΔN Hsp104 (75:1 Sup35 monomer to 
Hsp104 hexamer) promoted Sup35 amyloid fiber formation (Figure 1C). At high concentrations, 
WT Hsp104 inhibits the formation of amyloid fibers (instead shifting the species toward 
amorphous, ThT negative Sup35 aggregates), while ΔN Hsp104 continues to promote amyloid 
fiber formation (Figure 1C).  
 
2.2.2 Deletion of the NTD results in an increase in ATPase rate 
Since we found the NTD to be essential, in vitro, for the inhibition of Sup35 amyloid 
formation, we sought to determine what role the domain plays in hexamer function. Since ATP 
hydrolysis is required for the successful remodeling of Sup35 amyloid fibers [20], we wanted to 
test whether the ATPase rate of the ΔN Hsp104 variant was altered. The NTD is not directly 
involved in ATP binding or hydrolysis, however, the NTD of homologous proteins have been 
shown to play a role in regulating these events in neighboring domains [144, 148, 183, 187]. 
Surprisingly, the ATPase rate of ΔN Hsp104 was approximately 2-fold higher than the WT 
Hsp104 (Figure 2A). This shows that while ΔN Hsp104 is unable to inhibit Sup35 amyloid 
formation, it is not a functionally inactive hexamer. Further, this finding supports a role for the 
NTD of Hsp104 in regulating the ATPase rate of the hexamer. 
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2.2.3 Deletion of the NTD does not affect maximal inherent disaggregase activity, but 
does increase sensitivity to ATP:ATPγS ratios 
We next wanted to assess whether the truncated hexamer was effective at in vitro 
amorphous aggregate remodeling, for which we used a luciferase reactivation assay, which 
assesses disaggregation and reactivation of chemically denatured firefly luciferase [132]. By 
supplementing reaction conditions with different ratios of ATP:ATPγS, Hsp104 is able to 
disaggregate amorphous aggregates in the absence of the Hsp70 system [113]. Since ΔN 
Hsp104 displayed an elevated ATPase activity we were curious to find out if the ideal ATP:ATPγS 
ratio would differ from that of WT Hsp104. Our findings were surprising. Although both the WT 
and ΔN Hsp104 hexamers reached a peak activity at a ratio of 1:1 ATP:ATPγS, the ΔN hexamer 
was much more sensitive to changes in nucleotide ratios than the WT protein (Figure 2B). At a 
ratio of 2:1 ATP:ATPγS, WT Hsp104 shows statistically insignificant differences in activity to the 
WT protein at a ratio of 1:1 ATP:ATPγS. However, ΔN Hsp104, which shows no statistically 
significant difference in activity compared to WT Hsp104 at a ratio of 1:1 ATP:ATPγS is only 
about 50% (p < 0.02) as active as WT Hsp104 at a ratio of 2:1 (Figure 2B). This finding indicated 
that while the ΔN Hsp104 retained activity under specific conditions, it had lacked the robustness 
needed for activity at a broad range of ATP:ATPγS ratios.  
 
2.2.4 Deletion of the NTD leads to changes in conformation of the Hsp104 hexamer 
To determine the basis for the specific defects of ΔN Hsp104, and to use these findings 
to enhance our understanding of the WT protein, we wanted to visualize changes in the shape of 
the hexamer through the ATPase cycle for WT Hsp104 as well as ΔN Hsp104. For this we used 
the in solution structural technique Small (and Wide) Angle X-ray Scattering (SAXS/WAXS). To 
simulate the steps of the ATP hydrolysis cycle, in solution scattering experiments were carried out 
on the full-length protein (WT) and ΔN Hsp104 in six different states: in the presence of AMP-
PNP, ATPγS, ATP, ADP-AlFx (an ATP hydrolysis transition state mimic), ADP, and no nucleotide.  
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Monodispersity of both the WT and ∆N Hsp104 constructs was assessed using size 
exclusion chromatography coupled to multi-angle light scattering (SEC-MALS). A single peak 
elutes as expected for a hexameric assembly, and using the inline multi-angle scattering and 
refractive interferometer, an exact molecular weight can be calculated which corresponds to the 
theoretical weight of the hexameric particle (Figure 3A). The molecular weights obtained by SEC-
MALS compare favorably to the theoretical molecular weights of the two hexamers (Figure 3A). 
Both WT and ΔN Hsp104 particles also have linear Guinier regions (Figure 3B) in all nucleotide 
states, indicating that there are no interparticle interactions such as aggregation [199]. We 
measured scattering for each sample at multiple concentrations as well as different beamlines 
(SSRL 4-2 and NSLS X9) and obtained similar results in each case (Table 1). None of the 
samples showed signs of aggregation or any other concentration-dependent effects. 
Examples of raw scattering profiles (I(Q) vs. Q, where Q=4π(sinθ)/λ) and a 
representative GNOM [200] fit to the experimental data are shown for WT and ∆N Hsp104 in the 
presence of ADP in Figure 4A. Distinctive features in the low Q region that are present in all of 
the WT Hsp104 samples but not the ∆N Hsp104 samples are highlighted by the inset in Figure 
4A. A summary of Rg and Dmax values is reported in Table 2, as calculated by the program GNOM 
[200] which uses an indirect Fourier transform to convert reciprocal space information into real 
space information. The values reflect the average (including standard error) of measurements at 
varying concentrations and two beamlines. The reproducibility of the measurement is evidence 
that the samples are well behaved and ideally suited for SAXS analysis. The change in Rg is 
displayed as a bar graph in Figure 4B, with the nucleotide states ordered to represent a round of 
ATP hydrolysis (AMP-PNP, a non-hydrolysable ATP analog, ATPγS, a slowly hydrolysable ATP 
analog, ATP, which in our WT Hsp104 may be partially hydrolyzed, ADP-AlFx, an ATP hydrolysis 
transition state mimic, ADP, and the no nucleotide state). These values represent the average 
dimensions of the Hsp104 hexamer in the presence of the various nucleotides.  
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The Rg and Dmax values indicate that in the absence of nucleotide the Hsp104 hexamer is 
expanded relative to the hexamer in the presence of nucleotide (Figure 4B, Tables 1 and 2). A 
decrease in hexamer dimensions occurs upon addition of nucleotide, the magnitude of which is 
reproducibly dependent on the identity of the nucleotide (Figure 4B, Tables 1 and 2). Compared 
to the WT Hsp104 hexamer, the magnitude of the decrease in the ∆N Hsp104 hexamer 
dimensions is markedly more pronounced in the transition from the no nucleotide to nucleotide 
bound state (Figure 4B, Table 2). This decrease indicates that in the absence of nucleotide the 
∆N Hsp104 hexamer is more expanded than the full-length protein. For both proteins AMP-PNP 
and ATPγS, non-hydrolysable and slowly hydrolysable ATP analogs respectively, have the 
largest Rg values (Figure 4B, Tables 1 and 2). The ADP-AlFx states have the smallest Rg (Figure 
4B, Tables 1 and 2). These data suggest that both WT and ∆N Hsp104 hexamers contract upon 
nucleotide binding, reaching their smallest dimension in the presence of the transition state mimic 
ADP-AlFx, and then expanding slightly in the ADP state (Figure 4B, Table 2). This finding 
indicates that the hexamer contracts and expands in concert with ATP hydrolysis (Figure 4B,  
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Tables 1 and 2). The Dmax values for the WT and ∆N Hsp104 hexamers are comparable to each 
other for all of the nucleotide states, suggesting that the maximum dimension maybe a 
longitudinal rather than a simple N- to C- terminal vector (Tables 1 and 2). 
 Additional information about the conformational changes of the hexamers can be 
garnered from the real-space pairwise density distribution function, or P(r), which is also obtained 
by the indirect Fourier transform of the raw scattering data by the program GNOM [200]. 
Representative P(r) curves for the WT (Figure 5A) and the ∆N (Figure 5B) hexamers are shown 
for all nucleotide states. For ease of comparison the curves have been normalized to the area 
under the curve and overlaid. The area surrounding the peak of the P(r) curves has been 
enlarged as an inlay to show the differences between nucleotide states (Figure 5). As with the Rg 
values there are clear changes in shape dependent upon the identity of the nucleotide. Not 
surprisingly, the most striking difference is seen in the ∆N Hsp104 hexamer in the absence of 
nucleotide, where the particle is enlarged compared to the nucleotide bound states (Figure 5B).  
 The P(r) curves demonstrate that the addition of nucleotide, and the identity of the 
nucleotide, induces specific conformational changes in both the WT and ∆N Hsp104 hexamers. 
However, how the Hsp104 hexamer responds to nucleotide, both in terms of the magnitude and 
the specific effect of a given nucleotide, differs in the absence of the NTD. To visualize these 
changes, and how they differ between the WT and ∆N Hsp104 hexamers we used an ab initio 
modeling program GASBOR [201] to acquire volume reconstructions of the average shape of the 
particles in each nucleotide state (Figures 6 and 7). For each state, GASBOR was run on the raw 
scattering data 10 times. The outputs of each GASBOR run were then averaged together to give 
a filtered and unfiltered density using the program DAMAVER [202]. An overlay of every 
GASBOR output for each state is shown in Figure 6. The WT shape reconstructions were 
oriented using the ∆N hexamers (Figure 7B) which when overlaid showed where density for the 
missing domain would fit. The large conformational changes are clearly visible, in particular the  
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placement of a projection of external density. This projection is evident in the P(r) as well, as a 
population of large vectors evidenced by the P(r) tails that start around 175 Å, that represent a 
small amount of overall density (Figure 5). Both the WT and ∆N Hsp104 hexamers appear to 
have dynamic projections that travel from more N- to C- terminal positions through the simulated 
ATPase cycle (Figure 7A and C). The relatively large Rg and broadened P(r) curve of the ∆N 
Hsp104 hexamer in the absence of nucleotide is explained by the expanded cavity as seen by the 
view down the center of the reconstruction (Figure 7C).  
 Being able to visualize the average shape of the hexamers in each nucleotide state 
allows us to define how the particle changes through the nucleotide cycle. However, we know that 
the remodeling activity of Hsp104 is dependent upon translocation of substrate either fully or 
partially, through the central pore of the hexamer [167]. To understand how the central channel 
changes through the ATPase cycle we reconstructed the volume of the channel from the 
averaged GASBOR reconstructions (Figure 8). The average diameter of the channel 
reconstructions, N- C- terminally, are shown as bar graphs in Figure 8A (for WT) and Figure 8B 
(for ∆N). Each bar represents one angstrom, and the number of bars represents the length of the 
channel that is closed for 360 degrees. The motions of the WT Hsp104 channel are highly 
reminiscent of a peristaltic wave (Figure 8A). In a peristaltic wave there is a relaxation at the site 
of substrate entrance, followed by a wave of constriction that travels in the direction the substrate 
is being pumped . Experiments have shown that substrate enters N-terminally and can be fully 
translocated out the C-terminal end of the channel [111]. In the ATPγS/ATP states, when the 
hexamer is capable of binding substrate, the extreme N-terminal side is open (Figure 8A). After 
the opening there is a region of constriction, still N-terminal (Figure 8A, arrow). As we step 
through the simulated ATPase cycle, the channel first constricts fully, correlating with the smallest 
Rg, in the ADP-AlFx transition state mimic, and then the point of constriction moves toward the C-
terminus in the ADP state (Figure 8A). This peristaltic pumping motion, similar to how an 
esophagus moves food boluses, explains how the Hsp104 hexamer is able to transduce energy 
from ATP hydrolysis to conformational change and substrate remodeling using physical force. 
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 The role of the NTD in facilitating the peristaltic pump motion is both simple and 
significant. It becomes clear looking at the channel reconstructions why, in the absence of 
nucleotide, the ∆N Hsp104 hexamer is expanded (Figure 8B). In the absence of nucleotide, in the 
WT Hsp104 channel, the N-terminal region is contracted and the entire assembly elongated and 
open on the C-terminal end (Figure 8A). In the absence of the NTD the channel is unable to 
contract, rather, the entire hexamer is smaller in the N- to C-terminal direction, and the channel 
appears to have a uniformly large diameter throughout (Figure 8B). As the ∆N Hsp104 channel 
progresses through the ATPase cycle, it is clear that the missing domain is essential for the 
proper movements of the channel. This defect is most obvious in the transition state mimic ADP-
AlFx, which is constricted in the center but open on both sides (Figure 8B). While there still 
appears to be an area of contraction that shifts N to C-terminally, it is clear that the peristaltic 
motion is greatly perturbed in the ∆N hexamer (Figure 8B). Specifically, it appears that substrate 
could more readily diffuse out of the N-terminal opening of the channel of the ∆N Hsp104 
hexamer.  
Our SAXS/WAXS findings indicate that deletion of the NTD results in expansion of the 
ends of the central cavity (similar to a cryo-EM study of the ∆N Hsp104 hexamer [136]), as well 
as abnormal changes of the central channel during the ATPase cycle (Figure 8). Since ΔN 
Hsp104 is unable to undergo nucleotide-dependent changes in the central channel similar to WT 
Hsp104, we hypothesized that these structural defects may result in a diminished ability to 
translocate substrate through the Hsp104 hexameric channel. 
2.2.5 Deletion of the HAP NTD results in an increase in Km, and a decrease in Vmax for 
casein degradation 
To determine whether ΔN Hsp104 had a translocation defect as implied by the 
SAXS/WAXS data we determined a Km and Vmax of casein degradation (Figure 9A) for both the 
full length and ΔN versions of HAP. HAP is an Hsp104 mutant (739-GSK-741 to 739-IGF-741) 
that is able to interact with the chambered peptidase ClpP [111]. HAP and ΔN HAP retain ATPase  
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activity that is indistinguishable from WT and ΔN Hsp104 respectively (Figure 2A). In the 
presence of ClpP, substrates that are translocated through the Hsp104 variant HAP are degraded 
rather than released [111]. Therefore, using FITC-casein as a substrate we are able to assess 
translocation efficiency by monitoring increases in FITC fluorescence as a proxy for casein 
degradation, as FITC-casein is translocated and degraded, FITC is released. The ΔN HAP variant 
displayed an increased Km as well as a reduced Vmax (Figure 9A), revealing that it is a less 
effective translocase as predicted from the SAXS/WAXS data. 
 
2.2.6 Deletion of the NTD results in a defect in substrate unfolding 
Next we wanted to ascertain whether ΔN Hsp104 also displayed a defect in substrate 
unfolding. To assess unfoldase activity we used a RepA1-70-GFP unfolding assay [113], where 
decreases in fluorescence are used to measure GFP unfolding. To track unfolding of our RepA1-
70-GFP substrate in the absence of subsequent refolding, we added GroELTRAP [203], which 
captures the unfolded RepA1-70-GFP and prevents it from refolding [203]. By using permissive 
ratios of ATP:ATPγS we see that WT Hsp104 robustly unfolds the RepA1-70-GFP substrate 
(Figure 9B and C). WT unfolding activity is strongest with a 1:1 ATP:ATPγS, but remains strong at 
a 2:1 ratio (Figure 9B and C). In contrast, ΔN Hsp104 has partial RepA1-70-GFP unfoldase activity 
at a 1:1 ATP:ATPγS, but is unable to unfold RepA1-70-GFP at a ratio of 2:1 ATP:ATPγS (Figure 9B 
and C). This result indicates 1) that ΔN Hsp104 retains some, but not WT levels of unfoldase 
activity, and 2) Hsp104 unfoldase activity is more sensitive to changes in ATP:ATPγS than 
luciferase reactivation is (Figures 2B and 9B), indicating that productive disaggregation of 
disordered luciferase aggregates makes different demands on the Hsp104 hexamer than full 
substrate unfolding. 
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2.2.7 The NTD of Hsp104 is essential for hexamer cooperativity 
Recent work in our lab revealed that WT Hsp104 employs different degrees of 
intersubunit coordination to remodel disordered aggregates versus amyloid aggregates [132]. 
Dissolution of disordered aggregates does not require global cooperativity (i.e., all subunits 
binding substrate and hydrolyzing ATP in concert, or in a specific order), rather, non-cooperative 
probabilistic substrate binding and ATP hydrolysis are sufficient (i.e., subunits binding substrate 
and hydrolyzing ATP independently of each other) [132]. In contrast, dissolution of amyloid 
aggregates requires global cooperativity of the hexamer subunits [132], and Hsp104 hexamers 
that contained subunits with defects in cooperativity were unable to remodel amyloid substrates 
[132]. Since ΔN Hsp104 is also unable to remodel amyloid substrates (Figure 1), displays defects 
in ATPase regulation (Figure 2A), and is unable to undergo conformational changes reminiscent 
of the WT Hsp104 hexamer (Figure 8), we hypothesized that the NTD may be necessary for 
hexamer cooperativity.  
To test this hypothesis, we used a mutant subunit doping strategy [132]. Hsp104 subunits 
with specific defects (such as ATP binding or hydrolysis) are mixed with WT, or in our case, ΔN 
subunits, to generate ensembles of heterohexamers. Incorporation of the mutant subunits to 
create heterohexamer ensembles occurs according to a binomial distribution dependent upon the 
ratio of WT:mutant [132] (Figure 10A). Since the heterohexamers assemble based on a binomial 
distribution, and the Hsp104 mutants retain no activity on their own, theoretical activities for each 
ratio of WT:mutant can be determined based on the fraction of each type of heterohexamer 
present at each WT:mutant ratio, and how many active subunits are required for activity [132] 
(Figure 10B). If cooperativity is dispensable for activity, then only one WT subunit per hexamer is 
required, and a linear decrease in activity would be expected [132] (Figure 10B, orange line). If 
global cooperativity is required, a steep decline in activity would be expected [132] (Figure 8B, 
blue line), and if some form of sub-global cooperativity (i.e., more than one but less than six  
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subunits binding substrate or hydrolyzing ATP cooperatively) were required, an intermediate 
curve [132] (Figure 10B) would be expected. For our doping experiments we used the full-length 
WT Hsp104 with mutants in the full-length background, as well as ΔN Hsp104 and mutants in the 
ΔN Hsp104 background. The mutants we used were double Walker B (DWB, E285Q:E287Q) 
which can bind, but not hydrolyze ATP, double pore loop (DPL, Y257A:Y662A) which is defective 
in substrate binding [204], and the combination mutant, DWBDPL (E285Q:E287Q:Y257A:Y662A) 
which cannot hydrolyze ATP or bind substrate. In doping experiments with DWB or DWBDPL, we 
saw that ΔN Hsp104 behaved similarly to WT Hsp104 (Figure 10C and D). Luciferase reactivation 
was very sensitive to DWB subunits, ~5-6 WT/ΔN subunits per hexamer are necessary for activity 
(Figure 10C). By contrast, luciferase reactivation was much less sensitive to DWBDPL subunits, 
and luciferase reactivation required only one functional subunit per hexamer (Figure 10D). These 
findings indicate that defects in ATP hydrolysis are tolerated as long as the subunits defective in 
hydrolysis do not bind substrate (the DWB variant has been described as a substrate ‘trap’ [161], 
since substrate binds in the ATP state, and therefore substrate would be prevented from 
translocating through the Hsp104 channel if some subunits were bound to ATP as well as 
substrate). It also tells us that even though ΔN Hsp104 displays deregulated ATPase activity, it 
behaves similarly to WT Hsp104 in response to the addition of ATPase-dead subunits. We 
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obtained very different results with the DPL subunits, which are defective in substrate binding. 
When we doped these subunits into the ΔN and full length WT Hsp104, we found that in the 
absence of the NTD results in a dramatic enhancement of activity in the presence of the DPL 
subunits (Figure 10E). This finding implies that in the absence of the NTD the Hsp104 subunits 
are behaving in a negatively cooperative manner in respect to substrate binding. This finding 
suggests that the NTD is essential for productive cooperativity of the Hsp104 hexamer, a finding 
strongly supported by the defects in the conformational changes seen in the SAXS/WAXS data 
(Figures 5, 7 and 8).  
 
2.2.8 Intersubunit cooperativity mediated by the NTD is essential for potentiation of the 
Hsp104 hexamer 
Through random mutagenesis our lab has discovered Hsp104 mutants that are 
potentiated and capable of remodeling diverse substrates involved in human proteinopathies that 
are intractable to WT Hsp104 [179]. These mutations, in motif 2 of the middle domain (MD), 
appear to relieve autoinhibition of the hexamer and display increased activity in a variety of in 
vitro assays as well as suppressing toxicity of human disease associated proteins in both S. 
cerevisiae and C. elegans [179]. We decided to test whether these potentiating mutations (A503S 
and A503V) could overcome the defects in cooperativity of ΔN Hsp104. We found that in the ΔN 
Hsp104 background the potentiating mutations were unable to suppress toxicity of TDP-43, FUS 
(TDP-43 and FUS are connected to amyotrophic lateral sclerosis [205]), or α-synuclein (α-
synuclein is connected to Parkinson’s disease [206]) (Meredith Jackrel, Figure 11A-C). Since we 
know that global cooperativity is required for remodeling amyloid substrates [132], and that TDP-
43, FUS and α-synuclein form highly recalcitrant aggregates, this finding provides further 
evidence that the NTD is essential for global cooperativity of the Hsp104 hexamer. Further, it 
would appear that cooperativity of the hexamer trumps potentiation conveyed through these 
missense mutations.  
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2.3 Conclusions 
We have found that the Hsp104 NTD is necessary for nucleotide-dependent 
conformational changes that allow productive hexamer cooperativity. While cooperativity is 
dispensable for disordered aggregate dissolution, it is necessary for robust and adaptable 
hexamer function. This deficiency in hexamer cooperativity due to defects in conformational 
changes results in a deregulated ATPase rate, diminished unfoldase and translocase activity, and 
an inability to remodel exceptionally stable substrates such as amyloid, even in the presence of 
potentiating mutations. This role in global cooperativity is unexpected and novel for an Hsp100 
NTD, and if unique to Hsp104 could explain why amyloid substrate remodeling has only been 
observed with Hsp104 and not its bacterial homologue ClpB.  
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Chapter 3: X-ray footprinting (XF) as a probe of Hsp104 solvation 
3.1 XF introduction 
The functional Hsp104 hexamer is large and highly dynamic with an expansive, solvent 
filled channel running the length of the macromolecule [136, 171]. In response to nucleotide 
binding and hydrolysis, the hexamer undergoes substantial changes in conformation [137, 176]. 
These changes in conformation are coupled to remodeling diverse substrates, from thermally-
denatured aggregates [110] to amyloid conformers [20, 81, 113]. To understand the details of 
these conformational changes and how they may be driving substrate remodeling, a clearer 
picture of Hsp104 structure and dynamics is necessary. Hsp104 is too large for NMR analysis 
and has been refractory to crystallization attempts, therefore high-resolution structural information 
is lacking. The bacterial homologue tClpB has been crystallized, but as a monomer [102]. Two 
hexameric models have been proposed, based on rigid body fits of homology-modeled Hsp104 
into cryo-EM maps [136, 171]. However, the models disagree dramatically, and dynamics of the 
hexamer have been poorly defined. Elucidating details about the hexameric Hsp104 and how it 
changes in response to nucleotide is important to understanding how these changes mediate 
substrate remodeling. 
We aimed to use a hybrid approach to learn structural and mechanistic details of the 
Hsp104 hexamer. By combining homology modeling of the individual domains, volume 
information from small angle x-ray scattering, crosslinking and mutational analysis, secondary 
structure information from hydrogen-deuterium exchange and solvation information from x-ray 
footprinting, we aimed to develop structural and mechanistic models that can explain 
observations from the literature as well as allow us to predict novel mechanistic details that can 
be tested biochemically. Central to our approach is the information garnered from synchrotron x-
ray footprinting experiments. X-ray footprinting is a technique that probes the solvent accessibility 
of the side-chains of a protein [207-209]. This allows for the identification of regions that are 
involved in conformational changes and protein-protein interactions [207-209]. 
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Synchrotron x-ray footprinting uses millisecond bursts of high-flux x-rays to produce large 
amounts of hydroxyl radicals through the radiolysis of water [207, 210]. Hydroxyl radicals are 
ideal footprinting reagents because of their similarity to water molecules, making them excellent 
probes for solvation, and their high and well-characterized reactivity with 19 of the 20 of the 
amino acid side chains [207, 211, 212] (excluding glycine). Once hydroxyl radical-mediated 
footprinting has been carried out on a protein sample, the oxidized products can be detected 
using quantitative liquid-chromatography-coupled mass spectrometry [211, 213] (Figure 1). 
Identification of the reaction products can be achieved using methods based on hydrogen-
deuterium (HD) exchange analyses [214, 215]. The abundance of unmodified and oxidatively 
modified versions of a peptide is used to calculate the fraction unmodified [207, 208, 216] (Figure 
1). For any given peptide, there can be a number of different modified versions, since each 
residue can undergo different modifications, and different side chains on the same peptide may 
be modified [207, 212, 213]. All singly modified peptides are quantified and added to the sum of 
modified peptide [207, 208, 213]. Peptides that have more than one modification are not included 
in the sum, as they may represent solvation-independent oxidation which can occur after the 
initial, solvent-dependent modifications [211, 217]. The fraction unmodified for each identified 
peptide is determined for a number of millisecond time points (Figure 1). The rate of hydroxyl 
radical-mediated oxidative modification of each peptide is determined by fitting the dose response 
curve to a first order decay [208, 213, 216] (Figure 1). At the longest timepoints deviation from the 
curve indicates solvation-independent over-oxidation and therefore must be removed from the fit 
[213]. MS2 data can be used to identify specific residues that are modified. There are also a few 
modifications that can only occur on specific residues, although the majority of modifications, +16 
and +14, can occur on 18 and 8 of the 20 amino acids respectively [212, 213]. Modification rates 
of peptides can be compared across samples by using a normalization factor [218, 219]. The 
normalization factor is determined by measuring the x-ray dose dependent oxidation and decay of 
a fluorescent dye, Alexa488 in each of the sample conditions [218].  
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In this study we present the hydroxyl radical footprinting of Hsp104 in three states: 
monomer, hexamer with ADP and hexamer with ATPγS. We used pepsin proteolysis and mass 
spectrometry followed by peptide analysis using a modified version of an HX processing program 
called ExMS-CL [220]. We used homology modeled Hsp104 domains, based off the tClpB crystal 
structure [102], as a foundation for our examination of the solvation state of each domain in 
different nucleotide bound states (see Figure 2 for rigid body fits into the SAXS/WAXS envelope). 
Our solvation results allowed us to explain phenomena reported in the literature, to make testable 
predictions about the role different regions play in Hsp104 structure and activity and to make a 
new mechanistic model of how conformational changes are coupled to substrate remodeling.  
 
3.2 Results 
3.2.1 Experimental logic 
Samples of the Hsp104 monomer and the Hsp104 hexamer in the presence of either 
ADP or ATPγS were exposed to millisecond bursts of synchrotron x-rays and immediately 
quenched as described in the methods. On this timescale of hydroxyl radical exposure, the main 
reaction products are oxidative modification of the side-chains rather than backbone cleavage or 
crosslinking [212, 216]. Using a pepsin column, followed by separation with a C18 column, 
Hsp104 peptides were injected into a mass spectrometer as described in methods. Using a 
modified version of ExMS [220], an unmodified pool of peptides for each Hsp104 state was 
created from four 0 ms timepoint MS/MS runs. Using this unmodified pool, ExMS-CL was used to 
search for modified versions of the peptides. The possible modifications vary by amino acid but 
have been well characterized [207, 211, 212]. ExMS-CL uses the primary oxidation products for 
each amino acid published by Kaur, Kiselar and Chance [213]. Each timepoint (2.5, 5, 7.5, 10, 
and 20 ms) was run through MS/MS in triplicate. Using the identification of modified and 
unmodified peptides by ExMS-CL and their intensities, Matlab was used to determine the fraction 
unmodified for each of the three MS/MS runs for each of the samples timepoints. Only singly  
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modified versions of the peptides were used, as further modification is likely to be solvent-
independent [211, 217]. Additionally, there are often more than one version of the modified 
peptide, due to the possibility of multiple types of modification occurring to any given residue, as 
well as the ability of many residues within a peptide to become modified (e.g. an entire loop may 
be exposed to solvent and contain several residues with approximately equal reactivities, and 
each of these can undergo multiple reactions resulting in products of different masses) [207, 212, 
213]. Which modification takes place, and which residue it takes place upon, is to some degree 
determined stochastically [207, 212, 213]. To circumvent these concerns, each example of the 
modified peptide was summed and added to the modified pool when calculating the fraction 
unmodified using Matlab. For each timepoint, these values were averaged together and the 
standard error determined. Each peptide was binned into one of three categories by the Matlab 
program; no time-dependent modification, sporadic modification, and time-dependent 
modification. For the peptides that displayed time-dependent modification, the program used the 
first four timepoints (0, 2.5, 5, and 7.5 ms) to determine the rate of modification by fitting to a first 
order exponential decay. The earliest timepoints were used due to evidence of over-oxidation in 
many of the 10 and 20 ms timepoints. Each of the fits was visually checked and manually refitted 
using Origin 8.1 when the Matlab program failed to converge onto a visually accurate fit to the 
data. If manual re-fitting of the curve was impossible, often due to low signal-to-noise, the peptide 
was discarded. There was background modification of many of the peptides, and most of the 
sporadically modified peptides when examined manually, did not appear to display any time-
dependent modification. For those peptides that did display time-dependent modification but were 
classified as sporadically modified by the Matlab program, Origin 8.1 was used to manually fit the 
curve. In a few cases, there does appear to be time-dependent modification, however, a good fit 
to the data was impossible. In those cases the rate of modification is listed as not determined 
(ND).  
To complement the solvation data from XF, we have also included HD exchange data 
generated by Alec Ricciuti in the Englander lab, biochemical data using a variety of techniques, 
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and an investigation of the mechanistic basis of mutation based on phenotypes found in the 
literature. Finally, we have used the data generated from our hybrid approach to understand local 
and global changes of the Hsp104 hexamer during the ATPase cycle and to build a model of how 
large conformational changes of the hexamer function to remodel substrate in an ATP-dependent 
manner. 
 
3.2.2 Peptide overview 
The monomer, hexamer with ADP, and hexamer with ATPγS have 339, 359 and 342 
peptides found in all three replicates of all six timepoints, respectively (Table 1). 122 (monomer) 
135 (ADP) and 78 (ATPγS) of those peptides showed time-dependent modification, although 
several had to be discarded because of irregularities, mostly due to the presence of methionine 
residues within the peptide, or poor signal to noise. After discarding suspect peptides we were left 
with 81 (monomer), 117 (ADP), and 54 (ATPγS) peptides that showed time-dependent 
modification that could be fit to a first order decay curve to yield rate information (Table 1). Tables 
2, 3 and 4 list all of the filtered modified and unmodified peptides for the monomer, hexamer with 
ADP and hexamer with ATPγS, respectively. In instances where the modified peptide was 
selected for fragmentation and MS2 analysis, the identity of the specific site of modification was 
determined. The majority of identified peptides are unmodified. For an overall assessment of the 
general solvation state, the peptide with the highest rate of modification is used to describe the 
rate of modification for all amino acids contained on that peptide. This method of displaying the 
data will result in an overestimation of modification rate (and therefore solvation) but this 
overestimation will be consistent through and between the three states. This display method 
allows us to uncover large changes in solvation between the samples for a given region. For 
example, when peptides in one sample show no or very low modification - such as < 1 per 
second – while similar peptides in another state show very high rates of modification – such as > 
50 per second. For a direct comparison of rates, we need to look at the rate information for the  
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same peptide for all the states. Table 5 lists identical peptides found in two or three of the states, 
which cover some of the regions of interest. The presence of nucleotide in our buffer affects the 
effective hydroxyl radical population (i.e. nucleotide quenches the oxidation of the sample). 
Therefore, all of the rates have been normalized to the monomer sample based on the Alexa488 
decay data [218, 219], with normalization factors of 2.35 and 2.04 for the hexamers with ADP and 
ATPγS, respectively. 
To begin my analysis of the XF solvation data of the Hsp104 hexamer, and to tease out 
relevant mechanistic implications I started by looking at each individual domain. I examined 1) 
regions of known functional importance, 2) regions that are heavily modified, and therefore 
solvated, and 3) regions that undergo large changes in solvation between states. I then used the 
XF data to make mechanistic and structural predictions about regions in each domain. After 
investigating each domain separately, I combined the findings to present an overall picture of 
changes in solvation in the Hsp104 hexamer and what they mean for its activity and regulation. 
3.2.3 The N-terminal domain (NTD)  
3.2.3.1 NTD overview 
As we learned from Chapter 2, the NTD of Hsp104 is crucial for hexamer cooperativity. 
However, details of how it functions remained unclear. The crystal structures of the N-terminal 
domains of various Hsp100 proteins, including the Hsp104 bacterial homologues ClpA [141], 
ClpB [142], and ClpC [143] have been solved. The NTDs are highly structurally conserved 
despite low sequence identity (e.g. 28% sequence identity between the ClpA and ClpB NTDs). 
They are very stable globular domains [141] made up of two imperfect repeats of four helical 
bundles [141] and are connected to the D1 domain by a highly mobile linker [141]. The repeated 
subdomains, R1 and R2, each contain four helices, H1-H4 and H1’-H4’ (Figure 3A). Hsp100 
proteins such as ClpA [141] and ClpX [221] contain a zinc binding site in their NTDs. Hsp104 
retains the histidine residues involved in zinc [141] binding but not the essential glutamic acid, 
while ClpB is missing both the acidic residue as well as one of the histidine residues. A loop  
87	  
	  
88	  
	  
 
 
connecting the two repeats, which in ClpA is highly acidic [141], is instead enriched in glutamines 
and prolines in Hsp104. The three glutamines in a row, 78-QQQ-80 are an interesting divergence 
from bacterial homologues considering that many yeast prions are asparagine and glutamine rich 
[90]. I have homology modeled the Hsp104 NTD based on the NTD of the E. coli ClpB [142] 
(Figure 3A, B, D, and E). Support for the accuracy of the Hsp104 NTD homology model, despite 
the low sequence identity, is the solvation state of helix H2’ (Figure 3A), residues 113-117. This 
helix, based on the homology model, is shielded from solvent, and indeed, a peptide 111-118 that 
covers the H2’ helix, while found only in the ATPγS hexamer, is unmodified (Table 4, Figure 3E).  
 
3.2.3.2 The N-terminal domain is involved in substrate binding 
When the Hsp104 NTD, homology modeled off the NTD of E. coli ClpB, is compared to 
the well-characterized NTD of ClpA [141], there is strong structural homology despite the low 
sequence identity (there is 25% and 30% sequence identity between the NTD of Hsp104 and 
ClpA or ClpB respectively, similar to the identity between the two bacterial homologues). A 
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conserved feature of the Hsp100 NTDs is a hydrophobic patch between H1 and H1’ [141]. We 
see that in the homology model of the Hsp104 NTD this hydrophobic patch appears to be 
conserved (Figure 3B). Interestingly, the hydrophobic patch region appears to be solvated in all 
three states (peptide 86-110, Table 5) and in fact, 4 hydrophobic residues in that region were 
identified by MS2 analysis as being specific sites of hydroxyl radical modification (residues A91, 
L92, V95, and L96, Table 5, Figure 3C-E). This indicates that this conserved region may have the 
capacity to interact with substrate in both the ADP and ATPγS states. Two acidic residues, D108 
and D114, which have been implicated in large-aggregate substrate binding in ClpB [150], are 
also near the hydrophobic patch. However, in a surface rendering of the domain it appears they 
may have only minimal surface exposure, and modification of D108 was only seen in the 
monomeric Hsp104 sample (modification of D114 was not seen in any state and the peptide that 
covers the area was unmodified in the hexamer with ATPγ). 
To test whether the NTD of Hsp104 is involved in substrate binding, we measured the 
affinity for a fluorescent substrate, FITC-casein, using a fluorescence polarization assay. We 
used the purified wild-type protein (WT) and a truncation mutant (ΔN) missing the NTD as well as 
the NTD-NBD1 linker. In the presence of ATPγS WT Hsp104 binds FITC-casein robustly with a Kd 
of 55 +- 7 nM (Figure 4A). In the same conditions ΔN Hsp104 binds FITC-casein with a Kd of 194 
+- 60 nM, showing a 3 - 4 fold decrease in affinity (Figure 4A). This result supports a role for the 
Hsp104 NTD in substrate binding. Mutagenesis studies would allow us to pinpoint specific 
residues involved in the substrate interaction. The hydrophobic residues identified through MS2 
as being oxidatively modified would be a good starting point. Since the binding surface may 
consist of a large, non-specific hydrophobic patch it may be necessary to substitute a number of 
residues (there are approximately 10 residues involved in the hydrophobic patch) or replace the 
hydrophobic residues with charged residues.  
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3.2.3.3 The N-terminal domain is involved in productive interaction with Hsp70  
Additional residues that were identified as oxidatively modified by MS2 analysis fall into 
two clusters, either A, in the beginning of the H1’ helix and in the H2’-H3’ loop, (residues T87, 
Y90, K94, S124, and S125) or C, at the end of H1’ and in the H1’-H2’ loop (residues I102, Q103, 
K107 and S109) (Table 1, 3 and 4, Figure 3). These two clusters of residues are in the same 
regions that were identified in ClpA to be involved in interactions with an adapter protein ClpS 
[141], which protects ClpA from autodegradation and targets ClpA to aggregated substrates 
[191]. This was surprising, since the middle domain (MD) of Hsp104 and its bacterial homologue 
ClpB have previously been identified as the site of interaction with Hsp70 proteins (the Hsp70 
chaperones are essential for in vivo Hsp104 activity) [172-175]. However, in the Hsp100 protein 
ClpC, which has a truncated version of the middle domain (motif 1 only) the crystal structure of 
the hexamer revealed that the adapter protein MecA made extensive contacts with both the MD 
as well as the NTD [143]. This could well be the case for Hsp104 as well, considering that the 
region of the MD found to interact with Hsp70, namely residues within motif 2 near the C-terminal 
end of helix 2 [178], are adjacent to the NTD in every hexameric model of Hsp104 [171, 222]. The 
second cluster of modified residues (C), at the end of H1’, is covered by peptides 99-110 and 
100-110 which display a 10-fold protection from HD exchange upon formation of an apo hexamer 
(Table 6). An increase in secondary structure upon hexamerization further suggests that the 
region may be available for protein-protein interactions, especially since the XF data indicates 
that it remains solvated and is therefore unlikely to be involved in a hexamer interface. 
Additionally, the residues 100-102 (which contains the oxidatively modified I102, Figure 3C, D) 
were identified as a potential Hsp70:Hsp104 binding site using peptide array technology [178], 
although the authors did not investigate the region beyond an initial identification. Their dismissal 
of the importance of this interaction may have been premature; NTD:Hsp70 interactions, 
especially so close to the substrate-binding hydrophobic patch may facilitate substrate release 
from Hsp70 for hand-off to Hsp104.  
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To test the role of the Hsp104 NTD in productive Hsp70 interaction we used a luciferase 
reactivation assay to assess the remodeling activity of WT Hsp104 and ΔN Hsp104 in a variety of 
conditions. First, we verified that the ΔN Hsp104 construct was capable of Hsp70-independent 
luciferase remodeling. In vitro, in the presence of ATP, Hsp104 is inactive in the absence of 
Hsp70/Hsp40 [113]. However, for reasons that are poorly understood, Hsp104 is active in the 
absence of Hsp70/Hsp40 by the addition of permissive ratios of ATP:ATPγS [113]. WT Hsp104 
has a maximal activity at a 1:1 ratio of ATP:ATPγS (Chapter 2), and at this ratio ΔN Hsp104 
displays statistically insignificant differences in luciferase reactivation (Figure 4B). This finding 
allowed us to assess defects in productive interactions with Hsp70 proteins, since the inherent 
ability of ΔN Hsp104 to remodel aggregated luciferase appeared intact. Keeping the identity of the 
Hsp40 protein constant, we used two different Hsp70 proteins, Hsc70, which is constitutively 
expressed [223, 224], and Hsp72, which is expressed during heat shock [224]. In the presence of 
Hsc70, ΔN Hsp104 retained only 40% WT Hsp104 activity, while in the presence of Hsp72, 86% 
(Figure 4B). Reductions in ΔN Hsp104 activity with both Hsc70 and Hsp72 were statistically 
significant, with p values of p < 0.02 and p < 0.05 respectively. The difference in activity between 
ΔN Hsp104 in the presence of Hsc70 versus Hsp72 indicates that the Hsp104 hexamer may 
interact differently (or more or less robustly) with different Hsp70 proteins. Since Hsp104 is over-
expressed in response to stress, it may not be surprising that there could be differences in the 
productivity of interactions with Hsp70 proteins whose roles vary in vivo (e.g. those whose main 
role is in helping nascent polypeptides fold versus those involved in survival during and after 
various stresses). Once again, mutagenic analysis would allow us to pinpoint residues directly 
involved in these interactions. A promising target is T87, which was identified as oxidatively 
modified in the hexamer with ATPγS (Figure 3C, E). This residue is just N-terminal to helix H1’ 
(Figure 3C, E). In ClpA an equivalent residue, T81, resides within the main ClpS binding site (site 
A) [141] and in ClpC the residue T31 has been shown to be essential for ClpC activity by 
mediating the interaction with MecA [143]. An alternative possibility would be that the NTD is  
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making contacts with the MD, stabilizing the interaction between the MD and Hsp70. Whether 
direct, or indirect, it is clear that the NTD plays a role in Hsp70 interaction.  
 
3.2.3.4 The N-terminal domain controls Hsp104 cooperativity through a network of 
NTD:NBD1:MD interactions that include the NTD-NBD1 linker  
To understand how the NTD may be communicating with neighboring domain(s) and how 
these interactions may change depending on the identity of nucleotide, we can first look for 
regions that undergo changes in solvation between different states. These regions include the 
beginning of helix 1 (residues 8-15), the loop between helix 2 and 3, the loop between helix 3 and 
4, and the linker between the NTD and NBD1 (Figure 3C-E). A peptide that covers the beginning 
of H1 starting at residue 8, appears to be unmodified in the hexamer with ADP, but has a rate of 
1.85 +- 0.33 s-1 in the hexamer with ATPγS (Table 5). The loop between H2 and H3, residues 41-
51, is covered by the peptide 39-53, which has rates for the ADP and ATPγS hexamers of 25 +- 
0.005 and 4.3 +- 1.5 s-1, respectively (Table 5). The loop between H3 and H4, residues 58-61, is 
covered by the peptide 55-64. This peptide is unmodified in the monomer, and has rates for the 
ADP and ATPγS hexamers of 3.6 +- 0.009 s-1 and 0.85 +- 0.18 s-1, respectively (Table 5). 
Additionally, this peptide displayed a 2-fold protection from hydrogen-deuterium exchange in the 
hexamer with ADP, and a 10-fold protection in the hexamer with ATPγS (Table 6). The linker 
between the NTD and NBD1 is covered by the peptide 148-166 in all three states (Figure 3C-E). 
It is unmodified in the hexamer with ATPγS, has a rate of 0.101 +- 0.002 s-1 in the hexamer with 
ADP, and 0.215+- 0.014 s-1 in the monomer (Table 5).  
Then we can compare these regions from XF to the three tClpB monomer models. In the 
crystal structure of tClpB, each monomer of the spiral trimer (designated models A, B and C in 
the pdb) has a different orientation of the NTD [102]. By examining the different orientations of the 
NTD we discovered regions of the NTD, NBD1, and MD that appeared to be capable of 
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interacting in one or all of the three models. The homologous Hsp104 NTD residues include 8-20 
found in models A and B, NBD1 residues 264-274 found in models A and C, MD residues 496-
498 found in models A and C, and NTD residues 39-52, NTD/NBD1 residues 155-169, and NBD1 
residues 230-240 found in all three of the models. Many of these regions display changes in 
solvation, as mentioned above. These include the beginning of helix 1, residues 8-15 in particular 
(Figure 5 in yellow), which are protected from solvation in the hexamer with ADP, the loop 
between H2 and H3, residues 39-53 (Figure 5, in orange), which shows a decrease of solvation in 
the hexamer with ATPγS, and the NTD-NBD1 linker region, 148-166 which shows a protection 
from solvation in the hexamer with ATPγS. If we briefly investigate the regions in NBD1 and the 
MD we find that residues 230-240 (Figure 5, in blue) are covered by a number of peptides, which 
are always unmodified in both hexameric states (Tables 3 and 4). In fact, the peptide 225-243 is 
unmodified in the hexamers while the monomer has a modification rate of 15.9 +- 11.2 s-1 (Table 
5). Residues 262-274 display no clear trend in modification rate (Tables 2, 3 and 4), and residues 
496-498 (Figure 5, in green), covered by the peptide 494-504 are found unmodified in the 
monomer and the hexamer with ATPγS, but the peptide was not found in the hexamer with ADP. 
These findings indicate that the NTD, specifically the beginning of helix 1 in the hexamer with 
ADP, and the H2-H3 loop and NTD-NBD1 linker in the hexamer with ATPγS may be making a 
stable interaction with NBD1, specifically residues 230-240, and potentially the MD, in the loop 
between MD helices 2 and 3 in motif 2 (Figure 5). Since we know from Chapter 2 that the NTD is 
involved in regulating the ATPase rate and is essential for global cooperativity of the hexamer, we 
suggest that these interactions may mediate signals from substrate and/or Hsp70 interactions in 
the NTD to the rest of the hexamer. Further support of this model is the fact that an NTD mutant, 
T160M, which resides in a region proposed to interact with NBD1 and/or the MD was found to 
mimic the NTD deletion phenotype in vivo [154]. Additionally, other regions identified by peptide 
array as potential Hsp70 binding sites include residues 34-39 [178], just N-terminal of the H2-H3 
loop, and 241-249 [178], just C-terminal of the unmodified 230-240 NBD1 region, indicating that 
there may be a complex network of NTD-NBD1-MD:Hsp70 interactions, which the XF solvation  
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data has allowed us to map (Figure 5). Mutations in this region, specifically D498V [179], T499D 
and I230N (Amber Tariq, Shorter lab unpublished data) lead to potentiated Hsp104 variants, and 
deletion of the NTD precludes this potentiation. These findings suggest that this interface is, in 
fact, important for hexamer regulation and activity. 
 
3.2.4 Nucleotide-binding domain 1 
3.2.4.1 AAA+ motifs 
We know from the literature that NBD1 is a high affinity, high turnover site for ATP 
binding and hydrolysis [140]. NBD1 is the main site of ATP hydrolysis for the Hsp104 hexamer 
[140], but does not drive hexamerization [140]. Since we know that ATP binding and hydrolysis is 
required for Hsp104 activity, we wanted to examine changes in solvation of the conserved AAA+ 
motifs between the hexamer with ADP and hexamer with ATPγS. Overall, the domain is more 
modified in the hexamer with ADP than the hexamer with ATPγS (Figure 6A-C), particularly in the 
regions involved in the conserved ATP binding pocket. The Walker A motif, residues 212-220, the 
Walker B motif, residues 280-285, the sensor-1 residue, T317 and the arginine finger, R334 are 
covered by peptides which suggest that in the hexamer with ATPγS the ATP binding pocket is 
protected from solvation (Figure 6A). The peptide 211-223 shows no modification in the ATPγS 
hexamer, but a rate of 32.6 +- 1.9 s-1 in the hexamer with ADP (Table 5). The peptides 282-299, 
283-299 and 286-310 also show no modification in the hexamer with ATPγS but rates of 75 +- 
0.58 s-1, 28 +- 0.42 s-1, and 27 +- 0.3 s-1 respectively in the hexamer with ADP (Table 5). The 
peptides 300-320 and 311-320, which cover the sensor-1 residue T317, show that the hexamer 
with ADP is much more solvated than the hexamer with ATPγS, with rates of 145.6 +- 3.4 s-1 and 
2.8 +- 0.03 s-1 for ADP and 0 and 0.37 +- 0.07 s-1 for ATPγS respectively (Table 5). Finally, the 
peptides 331-350 and 332-349 that cover the arginine finger R334 are unmodified in the hexamer  
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with ATPγS, and have rates of 133.5 +- 3.4 s-1 and 3.8 +- 0.3 s-1 in the hexamer with ADP 
respectively (Table 5). Additionally, residues in these regions were identified as modified by MS2 
in the hexamer with ADP including the essential Walker B glutamate, residue E285, as well as 
R333, the residue directly preceding the arginine finger R334 (Table 5, Figure 6A). A recent 
paper from the Tsai lab found that mutation of either R333 or R334 results in a loss of ATPase 
activity [225], indicating that both may be involved in the role of arginine finger. These differences 
in solvation (Figure 6A) indicate that the six conserved ATP binding pockets of NBD1 in the 
hexamer with ATPγS are either all occupied, or all either occupied or closed (i.e. unoccupied, but 
shielded from solvent). This observation would fit with hexameric structures of AAA+ proteins 
seen to have some sites occupied by nucleotide, and the consequent asymmetric conformational 
changes forcing other sites closed [226]. This steric hindrance of all sites binding ATP 
simultaneously has been postulated to contribute to substrate handling mechanisms [101, 137, 
226]. Regardless of whether the NBD1 nucleotide-binding sites are all bound to ATPγS or some 
bound and the rest closed, this situation is clearly not the case for the hexamer with ADP. In the 
presence of ADP, there is a large degree of solvation in the nucleotide-binding, which indicates 
that either the ADP is either not large enough, or not rigidly bound enough to fully protect the 
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participating residues, or that some sites are bound to ADP while others are open and unbound to 
nucleotide.  
 
3.2.4.2 Nucleotide-binding domain 1 contains a conserved loop with a potential role in 
substrate interaction 
Though two substrate-binding loops have been identified in Hsp104 [167], the incomplete 
defect in thermotolerance when the NBD1 loop is mutated [167] indicates that there may be 
additional regions of NBD1 involved in substrate binding. The canonical substrate binding loop, 
256-KYKG-259 [167], is oxidatively modified in both hexameric states, indicating that the loop is 
solvated and capable of substrate interaction (Figure 6A-C, Tables 3 and 4). Though rate 
information for identical peptides is unavailable for both states, peptides that cover the loop are 
have much higher rates of modification in the hexamer with ATPγS than for the hexamer with 
ADP (compare 10.6 +-5.3 s-1 and 18.2 +- 0.37 s-1 for peptides from the hexamer with ATPγS to 
0.51 +-0.12 s-1 and 1.15 +- 0.08 s-1 for peptides from the hexamer with ADP - Tables 3 and 4). As 
the Hsp104 hexamer primarily binds substrate in the ATP state [204, 227], it is unsurprising that 
the loop would be more exposed in the hexamer with ATPγS than in the hexamer with ADP. 
While Y257 has been identified as one of two substrate binding residues in Hsp104, 
thermotolerance assays show that mutation of the tyrosine to alanine results in only minor defects 
in Hsp104 mediated survival [167]. This is in contrast to mutation of the NBD2 tyrosine, Y662 to 
alanine, which results in large defects in survival after heat shock [167]. This finding led us to 
hypothesize that regions of the NTD as well as other sites within NBD1 may also contribute to 
substrate binding. As discussed in the preceding section, the NTD is indeed involved in substrate 
binding (Figure 4A). This finding is further supported by thermotolerance data showing that while 
either deletion of the NTD or mutation of Y257 display only mild defects in thermotolerance, the 
combined truncation and mutation variant, ΔN:Y257A Hsp104 is severely compromised in its 
ability to mediate survival after heat shock (Figure 7A). To determine if there are other substrate  
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binding regions of NBD1 we looked for regions that change in solvation in the different hexamers. 
A striking example stood out immediately. In the homology model of the Hsp104 NBD1 there are 
two loops that point into what would be the interior of the hexameric Hsp104 channel (Figure 6A-
C). One is the canonical 256-KYKG-259 loop and the second is the 291-GNGKD-295 loop. 
Peptides covering the 291-GNGKD-295 loop are unmodified in the hexamer with ATPγS, but 
highly modified in the hexamer with ADP (the peptides that cover the Walker B site also cover this 
loop) (Figure 6A-C, Table 5). In addition to the peptides (282-299, 283-299 and 286-310, Table 5) 
displaying high rates of modification in the hexamer with ADP (75 +- 0.58 s-1, 28 +- 0.42 s-1, and 
27 +- 0.3 s-1, respectively, Table 5) three residues within and near the 291-GNGKD-295 loop 
were identified as modified by MS2, including N292, and K294 (Figure 6A). This loop is 
homologous to the ClpC 286-GAGGA-290 [143] loop, as well as the ClpA 292-GAGAA-296 [168] 
loop, which are secondary substrate binding loops. Mutation or deletion of this loop results in 
severe defects in ClpC [143] and ClpA [168] activity. 
We decided to test our hypothesis that this loop is involved in substrate processing in 
Hsp104. To assess whether this loop is actually necessary for Hsp104 activity, we carried out in 
vivo thermotolerance and in vitro luciferase reactivation assays, as well as fluorescence 
polarization assays to test for differences in Kds. Fluorescence polarization experiments revealed 
that mutations in the loop, N292A, K294A and D295A, had no statistically significant effect on 
FITC-casein binding in the presence of ATPγS (Table 7). This result was to be expected since the 
loop appears to be protected from solvent in the hexamer with ATPγS, and is therefore unlikely to 
interact with substrate in this state. Since initial and robust substrate binding appears to occur in 
the Hsp104 hexamer with ATP, one possibility is that this second loop transiently engages the 
substrate during or after ATP hydrolysis to ADP. This interaction could prevent substrate diffusion 
as the subunits in the hexamer rebind ATP and subsequently reengage the polypeptide at a new 
site, thereby driving directional translocation of the substrate. We decided to test whether there 
were differences in FITC-casein binding in the presence of ADP. WT Hsp104 binds FITC-casein  
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in the presence of ADP with a Kd of 5.9 +- 0.7 µM, 2 orders of magnitude weaker than in the 
presence of ATPγS. When we tested our loop mutants, we found that once again there were no 
statistically significant changes in affinity (Table 7). And this may not be surprising. If our model is 
correct, substrate would first need to engage the Hsp104 hexamer in the presence of ATPγS, and 
then be handed off to the second loop. In our experimental set-up the Hsp104 hexamer is 
incubated with ADP and then FITC-casein is added. In these conditions we may not expect 
substrate to bind in a manner indicative of how the Hsp104 hexamer normally processes 
substrate. 
In vivo thermotolerance assays revealed that the K294A Hsp104 variant displayed a 
slight, but statistically significant (p=0.05), defect in mediating survival after heat shock compared 
to WT Hsp104 (Figure 7A, work of Michelle Go, Shorter lab). When the K294A mutation was 
combined with the NTD truncation, survival after heat shock was similar to the ΔN:Y257A variant 
(Figure 7A, work of Michelle Go, Shorter lab). The double mutant Y257A:K294A variant was less 
active than the single mutants, but more active than the single mutants combined with the NTD 
truncation (Figure 7A, work of Michelle Go, Shorter lab). This in vivo data supports a role for the 
loop in substrate processing. We then wanted to test the mutants in an in vitro assay with minimal 
components so that we could remove the confounding and potentially mitigating effects of the 
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presence of various Hsp70 and other chaperone proteins. To test the activity of the loop mutants 
in a minimal component situation, we carried out luciferase reactivation assays in the presence of 
a 1:1 ratio of ATP:ATPγS. What we found was that the loop mutants N292A, K294A and D295A 
were defective in luciferase reactivation, retaining only 20%, 39% and 19% of WT Hsp104 
respectively (Figure 7B). This finding confirmed the importance of this loop for productive 
substrate remodeling, and indicates that defects caused by mutations in the loop can, in fact, be 
partially mitigated by the in vivo environment. Ideally we would be able to test whether our 
proposed mechanism for the loop, preventing substrate diffusion as subunits rebind ATP, is 
correct. An assay designed to measure release of substrate due to ATP hydrolysis after initial 
binding events would be able to confirm whether mutations in the loop result in more, or faster 
release of substrate. An alternative would be to measure processivity of the WT and mutant 
Hsp104 variants. 
 
3.2.5 Solvation of the middle domain changes dramatically in the presence of different 
nucleotides, which supports a role in Hsp104 regulation 
We aimed to use information from the literature as well as our solvation data from the XF 
experiments to get a holistic understanding of how local and global dynamics of the MD 
determine its role in regulating the hexamer. The homology model of Hsp104’s anti-parallel 
coiled-coil middle domain (MD), based off of the tClpB structure, retains the leucine zipper-like 
interactions between the helices 1-4 (Figure 8B and C). The arrangement of large hydrophobic 
residues such as leucine and isoleucines at the helical interfaces, with polar and charged 
residues exposed on the other side of the helices, is an indication that the model is sound. 
Additionally, hydrogen-deuterium exchange experiments confirm the loop-secondary structure 
boundaries (data not shown, Alec Ricciuti and Walter Englander manuscript in preparation). The 
MD has been implicated in regulating the ATPase rate and activity of the hexamer [136, 145, 172, 
173, 175-177, 228-230], transmitting signals between NBD1 and NBD2 [181, 228, 229], and  
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mediating the interaction with Hsp70 [172-175, 178]. Interactions with Hsp70 proteins have 
shown to take place in motif 2, specifically residues 480-KKK-482 and residue R496 [178]. We 
have already discussed in the preceding sections how these regions are poised to interact with 
the NTD as well as NBD1 (Figure 5). In ClpB a number of interactions between motif 2 of the MD 
and NBD1 have been identified [102, 172, 176, 231] and it has been shown that stabilization of 
these interactions leads to repression of the disaggregase [102, 172, 176], while destabilization 
leads to potentiation [102, 176, 179, 231]. While the models in Figure 8 show the MD partially 
projecting into solution, it is simply representative of one possible orientation. XF data as well as 
published crosslinking [176, 222] and structural data [176] support a model in which the domain is 
highly mobile, undergoing interactions with both NBD1 [102, 172, 176, 231] and NBD2 [222]. 
Additionally, it is likely that MDs within a given Hsp104 hexamer occupy a variety of positions 
[176]. The orientation shown in Figure 8 is fit into a symmetrically averaged volume envelope, 
and future work would include modeling the domain asymmetrically into the hexamer in a variety 
of positions based on a compilation of the published data and XF information 
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 XF data of the MD shows large changes in solvation between the hexamer bound to 
ADP and the hexamer bound to ATPγS (Figure 8A-E). This finding is to be expected since the 
domain is highly dynamic, and restricting its movement through disulfide crosslinking greatly 
impairs Hsp104 activity [102, 172, 222]. In general, the hexamer with ADP displays greater 
solvation than the hexamer with ATPγS (Figure 8A-E, Tables 3-5). The only part of the MD where 
this is not true is the first three residues of the MD, 412-414, found on the peptide 405-414, which 
mainly covers the NBD1 domain (Table 5). This peptide is solvated in both hexameric states, but 
more so in the presence of ATPγS (compare 21.5 +- 0.4 s-1 to 52.8 +- 9.5 s-1, Table 5). 
Modification rates change at the adjacent peptide. The peptide 415-423 shows that the hexamer 
with ATPγS is unmodified while the hexamer with ADP has a modification rate of 35.5 +- 0.8 s-1 
and contains several residues identified as modified by MS2: D415, S416, K417, E418, L421 and 
L423 (Table 5, Figure 8A).  
This peptide covers the first half of helix 1, and is adjacent to a region of helix 2, residues 
456-466, which is also unmodified in the hexamer with ATPγS (Figure 8C, see arrows). This 
peptide, 456-466, has a modification rate of 1.8 +- 0.5 s-1 in the hexamer with ADP and contains 
residues identified as modified by MS2, E457 and E460 (Table 5, Figure 8A). A region more C-
terminal in helix 2, residues 467-474, is unmodified in the hexamer with ADP, but is modified in 
the hexamer with ATPγS. A peptide that covers this region, 467-493, is unmodified in the 
hexamer with ADP, and has a modification rate of 0.84 +- 0.1 s-1 in the hexamer with ATPγS 
(Table 5). Interestingly, the same peptide shows large changes in protection from deuterium 
exchange. From monomer to apo hexamer to hexamer with ADP to hexamer with ATPγS the 
peptide undergoes increases in protection from 2- to 10- to 50-fold respectively (Table 6, Alec 
Ricciuti). The changes in solvation and secondary structure indicate that transitions in this region 
of helix 2 may play a role in transmission of conformational changes from motif 1 to motif 2 in 
response to stimuli (e.g., interaction with Hsp70, binding of substrate in the NTD and NBD1, and 
ATP hydrolysis at NBD1 or NBD2). It’s been shown that the MD is crucial for communication 
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between NBD1 and NBD2 [181, 228, 229], for example, in ClpB ATP binding in NBD1 leads to 
large movements of the MD and subsequently promotes hydrolysis in NBD2 [229] (this 
communication route may be reversed in Hsp104 since the role of the two nucleotide binding 
domains is transposed between ClpB and Hsp104 [135], or could be bi-directional). Additionally, 
a mutation in this region, L462R, was discovered to disrupt intersubunit cooperativity [132], 
suggesting that this region is critical for communication within the Hsp104 hexamer. 
Several crosslinks between motif 2 of the MD and NBD1 have been found, in ClpB: 
G175C:S499C [172], D178C:S499C [172], G167C:R475C[102], V350C:Q467C[102], 
G353C:R464C[102], R355C:E520C[102], K476C:E358C[176] and in Hsp104 there may be a salt 
bridge D484:D184:K358 [231]. Models proposing that this motif 2-NBD1 interaction is dynamic 
are supported by the solvation data which shows large increases in solvation in the hexamer with 
ADP compared to the hexamer with ATPγS (Figure 8A-E). These increases in solvation include 
the C-terminal end of helix 2 (Tables 3 and 4) as well as the end of helix 3 through the end of the 
MD (peptides 505-526, 506-522, and 508-536 with rates for the hexamer with ADP of 350 +- 0.9 
s-1, 20 +-1.2 s-1, and 89 +- 3.4 s-1 respectively versus 0 s-1, 1.5 +- 1 s-1, and undetermined for the 
hexamer with ATPγS) (Table 5). Residues 494-504 are not found in the hexamer with ADP but 
are unmodified in the hexamer with ATPγS. This finding indicates that helices three and four of 
motif 2 are partially shielded from solvent in hexamer bound to ATPγS. If this protection from 
solvent is representative of the repressive motif 2-NBD1 contacts it would support a model where 
the repressed state of the hexamer is predominantly found in the hexamer with ATPγS. This 
would make sense since ATP hydrolysis is necessary for substrate remodeling. Additionally, 
several potentiating mutations are found in helices 3 and 4 [102, 176, 179, 231] (Dr. Meredith 
Jackrel, unpublished work), indicating that large changes in solvation between nucleotide bound 
states may indicate mechanistically important regions of the Hsp104 hexamer. 
More recent work in our lab uncovered robust crosslinks between motif 1 of the MD and 
NBD2, A430C:F630C, and K451C:E790C [222] and mutations in the distal loop (R433-R441) 
110	  
	  
revealed that the region is crucial for transmission of Hsp70-mediated relief of the MD 
autoinhibition [222]. These crosslinks were predicted by a hexameric Hsp104 model in which the 
MD is intercalated between the NBDs [136, 137]. Confirmation of these crosslinks means that the 
MD cannot invariably project into solution as proposed in a second hexameric model of Hsp104 
[171]. The XF data shows that the distal loop is more solvated in the hexamer with ADP than the 
hexamer with ATPγS (peptide 431-455 with rates of 0.57 +- 0.009 s-1 and 0.08 +- 0.05 s-1 
respectively, Table 5) and that the region around residue 630 is also more solvated in the 
hexamer with ADP than the hexamer with ATPγS (peptide 611-631 with rates of 4.9 +- 2.2 s-1 and 
0 s-1 respectively, Table 5). Peptides covering the NBD2 residue involved in the second crosslink 
are similar, with rates for the hexamer with ADP much higher than for the hexamer with ATPγS 
(peptides 789-806 and 789-809 which are unmodified in the hexamer with ATPγS but have rates 
of 22.3 +- 0.3 s-1 and 20 +- 0.2 s-1 respectively for the hexamer with ADP, Table 5). All of these 
XF modification rates match the crosslinking data well, since the crosslink was most robust with 
AMP-PNP, less so with ATP, and even less with ADP [222]. Therefore, data from multiple 
techniques confirms that the interactions of the MD and NBD2 are stabilized in the hexamer with 
ATPγS compared to the hexamer with ADP. These motif 1 MD-NBD2 crosslinks reveal a missing 
piece to the NBD1-MD-NBD2 communication network, and the changes in solvation and 
secondary structure at the juncture of motif 1 and motif 2 found by XF and hydrogen deuterium 
exchange explains how signals may be transmitted through the coiled-coil between the two 
nucleotide binding domains in response to ATP hydrolysis and Hsp70 binding.  
 
3.2.6 Nucleotide-binding domain 2 
3.2.6.1 AAA+ motifs  
First, we will examine modification of the conserved NBD2 ATP binding motifs as well as 
the region that contains the nuclear localization signal (NLS) [157]. There is no coverage of either 
the arginine finger or the sensor 1 residue. Similarly to our findings in NBD1, a peptide 684-697 
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that covers the Walker B motif is unmodified in the hexamer with ATPγS but has a rate of 49 +- 
1.3 s-1 and two residues identified by MS2 as being modified, L684, and the conserved glutamate, 
E687 in the hexamer with ADP (Table 5). Additionally, the peptide 813-831 that covers the sensor 
2 residue (R826), is unmodified in the hexamer with ATPγS and has a rate of 42 +- 0.2 s-1 in the 
hexamer with ADP (Table 5). However, just C-terminal of the Walker B motif is a peptide 688-
696, which in the hexamer with ATPγS has a modification rate of 57 +- 9.4 s-1, and a peptide 613-
623 which covers the Walker A motif has a rate of 9.5 +- 0.3 s-1 in the hexamer with ATPγS with 
residues 616 and 618 have been identified by MS2 as modified (Tables 4 and 5). These data 
indicate that in contrast to NBD1, ATPγS binding in NBD2 does not fully shield the nucleotide-
binding pocket from solvent. This may be due to the presence of empty, incompletely closed 
sites, and/or less stable ATPγS binding, which would result in partial solvation of some of the 
sites with the Hsp104 hexamer population. Differences between NBD1 and NBD2 are not 
surprising, as they belong to different AAA+ clades [155] and are responsible for divergent 
functions within the Hsp104 hexamer [140]. 
 
3.2.6.2 Nucleotide-binding domain 2 nuclear localization signal (NLS) 
The NLS in Hsp104, residues 773-789 [157], appears to be solvated in the monomer as 
well as both of the hexameric states, with the hexamer with ATPγS the least modified (Table 5, 
Figure 9). The NLS also includes the NBD2 hinge 773-NKLS-776, which connects the large and 
small subdomains of NBD2. Peptides that cover this regions include 769-785 and 786-806 with 
rates for the monomer, the hexamer with ADP and the hexamer with ATPγS of 1.15 +- 0.1 s-1, 
0.64 +- 0.003 s-1, and 0.14 +- 0.02 s-1 respectively for 769-785 and 0 s-1, 17.6 +- 6.3 s-1, and 0 s-1 
respectively for 786-806 (Table 5). There are many MS2 identified modified residues in this 
region, including lysines (in bold) which, when all mutated to alanine result in a loss of nuclear 
accumulation [157], as well as residues (in italics) that are in the NBD2 hinge. K774 may or may 
not be necessary for nuclear localization; since it is in the NBD2 hinge mutating it to alanine  
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disrupts the protein’s stability. The MS2 identified residues include (all found on the peptide 769-
785): N773, K774, S776, K778, A779, I780, H781, K782, and V784 in the monomer, F772 (just 
before NLS), K774, H781, K782, I783, V784 found in the hexamer with ADP, and F772, K774, 
S776, R777, I780, K782 found in the hexamer with ATPγS (Table 5, Figure 9). It would appear 
that K782 is always exposed to solvent, and in the monomeric state the hinge is highly exposed 
(3 of 4 NBD2 hinge residues were identified as modified, compared to the hexamer with ATPγS (2 
of 4) and the hexamer with ADP (1 of 4)). The third essential lysine, K789 [157] is not on the 
peptide 769-785 and therefore we have not confirmed its solvation state.  
 
3.2.6.3 A hexameric model of nucleotide-binding domain 2 which is consistent with the XF 
solvation data  
The second nucleotide-binding domain (NBD2) is necessary and sufficient for Hsp104 
hexamerization [160], however, a hexameric interface has yet to be described. We have used the 
monomeric NBD2 modeled off of the tClpB structure to create a hexameric NBD2 model (Figure 
9B and C). This model uses the equivalent subunit:subunit interfaces seen in the hexameric ClpC 
[143] and ClpX [226] structures, and fits previously published crosslinking [225] and mutational 
data [182]. This interface includes helix 3 and part of its C-terminal loop in the large NBD2 
subdomain (residues 586-AIKAVSNAVRLSRSGL-601, with conserved hydrophobic residues in 
bold), and the last helix and part of its C-terminal loop in the neighboring NBD2 small subdomain 
(residues 836-ILNKLALRILKNEI-849, with conserved hydrophobic residues in bold) (Figure 9).  
There are a large number of conserved, hydrophobic residues in these regions indicating 
that they may be mediating the subunit:subunit interaction. If the subunit:subunit interaction was 
driven by hydrophobic interactions, it would explain a number of previously published 
phenomena. We know that the protomer interface undergoes large changes in conformation 
during the functional cycle of the hexamer; crosslinking the small and large subdomains results in 
stable hexamers with diminished function [225]. If the interface was a rigid salt bridge, it may 
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hinder rapid and smooth movements of the domains. If instead the region were a network of 
hydrophobic residues then the interface could easy change register upon conformational changes 
of nearby regions. The proposed interface is ideally suited to respond to changes in nucleotide – 
while the C-terminal end of the small NBD2 helix contains a number of conserved hydrophobic 
residues that we propose to be involved in the hexamer interface, the N-terminal end contains a 
region called the sensor and substrate discrimination (SSD) motif, which contains a sensor 2 
arginine (R826) [102] (Figure 9). Additionally, the helix and loop in the NBD2 large domain that 
we propose to be involved in the interface is just N-terminal to a short, highly conserved β-sheet 
that immediately precedes the conserved Walker A motif [102].  
A hydrophobic interface would also explain why the Hsp104 hexamer is sensitive to salt 
[140]. As salt concentrations increase, the Hsp104 hexamer becomes destabilized [140]. Upon 
cursory inspection, this finding would make it seem unlikely that the interface were mediated by 
hydrophobic interactions, however, Hsp104 undergoes continual and rapid monomer exchange 
[132]. Upon mixing Hsp104 hexamers with different (measurable) properties, monomer exchange 
occurs on a timescale of just a few minutes to yield an ensemble of hexamers containing subunits 
of different Hsp104 variants explained by the binomial distribution [132]. This phenomena of 
monomer exchange explains why high salt conditions would disrupt hexamer integrity, as a 
monomer is released from the hexamer into high salt conditions, there will be a propensity to 
make intramolecular contacts in order to bury the newly exposed hydrophobic hexamer interface. 
We find support for this hypothesis by examining the solvation information from the XF 
modification data. In the monomeric sample, which was created by adding 500 mM NaCl to the 
buffer, there are two regions, one N-terminal to helix 3 of the large NBD2 domain (residues 569-
583), and one C-terminal of the small NBD2 domain helix (residues 843-857), which become 
shielded from solvent (Figure 10A, Table 2). Though there is no coverage of 569-583 in the 
hexamer with ATPγS, it is highly modified in the hexamer with ADP (Tables 3 and 4). The peptide 
843-857 is unmodified in the monomer and modified in both of the hexamers, with a number of  
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residues identified as modified by MS2 (3.8 +- 0.14 s-1 with residues R843, K850, E853, and 
V855 for the hexamer with ADP and 6.1 +- 4.5 s-1 with residues R843, L845, K846, E848, I849, 
K850, K852, and V857 for the hexamer with ATPγS, Table 5). Both of these regions also contain 
highly conserved hydrophobic residues [102], supporting the possibility that they may be involved 
in intramolecular interactions that block hexamerization in high salt.  
We decided to test whether we could disrupt the hexameric interactions by mutating a 
conserved hydrophobic residue in the proposed protomer interface to a charged residue. We 
chose L601 because it is in a loop region, so it was unlikely to grossly perturb secondary 
structure, and it is conserved in Hsp100 proteins from plants to bacteria to yeast [102]. Using a 
glutaraldehyde crosslinking assay [160] we assessed the ability of low concentrations of WT 
Hsp104, the double Walker A mutant (DWA - a variant known to severely disrupt hexamerization 
[160]) and a L601K variant to form hexamers under two conditions, adding either EDTA or ATP. 
Addition of EDTA chelates the magnesium essential for ATP binding and therefore disrupts the 
ability of Hsp104 to form hexamers, while addition of ATP promotes the formation of hexamers 
[139]. We visualized the gels using silver stain and found that WT Hsp104 exists as a mixture of 
monomer, dimer, trimer and hexamer in the presence of EDTA, and upon addition of ATP shifts 
entirely to the hexamer (Figure 11). DWA Hsp104, our negative control, shows very little hexamer  
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in the presence of EDTA, and upon addition of ATP remains a mixture of monomer, dimer and 
trimer (Figure 11). The L601K Hsp104 mutant appears to strongly resemble the DWA Hsp104 
variant; even upon addition of ATP there is very little hexamer but instead mostly smaller 
oligomers and monomer (Figure 11). This data supports the potential placement of the residue 
near a hydrophobic hexamer interface. Future experiments include repairing the interface with a 
compensatory, oppositely charged residue in the small NBD2 domain, as well as disulfide 
crosslinking.  
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Once I had a proposed interface and hexameric model, I used the XF modification rate 
information to assess its validity. I have colored the NBD2 hexameric model based on the XF 
modification rates for the hexamer with ADP as well as the hexamer with ATPγS (Figure 10B and 
C). Despite large differences in solvation, both of the states agree well overall with the model 
(Figure 10B and C). The hexamer with ADP shows a high degree of modification, with only two 
regions that appear to be shielded from solvation. These regions include residues 646-670 which 
contain the canonical substrate binding motif 661-GYVG-664, as well as residues 838-NKLAL-
842, which reside within the region of the NBD2 small domain we propose to be involved in the 
hexamer interface (Table 3, Figure 10A). The fact that the rest of the domain appears to be 
solvated fits with the overall trend we have seen in both the XF solvation data and the HD 
exchange data, namely that the hexamer with ADP has less structure and more regions 
accessible to solvent. This suggests a model in which the energy of ATP binding induces the 
formation of stable secondary structure as well as minimizing large dynamic movements which 
would, due to the ensemble nature of XF experiments, result in increased regions of solvent 
accessibility. The implications for this finding will be explored further in a subsequent section. The 
hexamer with ATPγS has a number of regions that appear to have decreased modification rates 
and therefore solvation when compared to the hexamer with ADP (Figure 10A-C). When the 
modification rates are mapped onto our hexameric model we see a striking agreement (Figure 
10B and C). Regions that display no oxidative modification include the core of the globular NBD2 
domains, which in contrast to the hexamer with ADP, indicates that in the presence of ATPγS the 
domain is rigid, thereby protecting the interior of the domain from solvent. The substrate binding 
region is also unmodified in the hexamer with ATPγS, indicating that hydrolysis in NBD1 may be 
necessary to prime the GYVG loop for substrate engagement (Table 4). There is also substantial 
protection of the regions we believe to be involved in the hexamer interface. Though there is no 
coverage of the N-terminal part of the NBD2 large subdomain helix, residues in the middle show 
no modification, while residues on the helix near the surface of the hexamer show a low rate of 
modification (peptide 597-610 with a rate of 0.45 +- 0.17 s-1, Table 4). Similarly, the NBD2 small 
119	  
	  
subdomain helix is unmodified in the N-terminal end, which is the interior of the hexamer, while 
modifications increase C-terminally. The region of the helix positioned near the outside of the 
hexamer becomes increasingly modified (peptides 838-856 and 843-857 with rates of 0.12 +- 
0.009 s-1 and 6.12 +- 4.5 s-1 respectively, Tables 4 and 5).  
 
3.2.7 C-terminal domain 
Hsp104 has a unique C-terminal extension (CTD). The role of the CTD is poorly 
understood, though it is required for hexamerization [180, 182]. The XF data revealed a 
surprisingly unmodified stretch of acidic residues in the C-terminal extension (CTD), residues 
893-GDDDNEDS-900 (Table 4, Figure 10A). The protection of this acidic patch, predicted to be 
unstructured, may be an important clue to its role, however, since the region is unique and 
therefore cannot be modeled based off homology it is hard to predict where it might be interacting 
with the rest of the hexamer. One possibility is a region of low homology in the NBD2 large 
domain helices 10 and 11 [102], which is protected in the hexamer with ATPγS (peptides 733-744 
and 733-748 are unmodified in the hexamer with ATPγS and have rates of 1.8 +-0.02 s-1 and 103 
+- 3 s-1 respectively in the hexamer with ADP). In Hsp104 this region has a large number of polar 
residues as well as two lysine residues. Whether the two regions interact could be tested using 
disulfide crosslinking.  
 
3.2.8 Overall changes in solvation and hydrogen-deuterium exchange supports a new 
model for substrate remodeling by Hsp104 
Overall, the hexamer with ADP shows more modification in our XF experiments as well 
as more HD exchange than the hexamer with ATPγS (Tables 2-6). These findings indicate that 
the hexamer with ADP is more solvated and has less secondary structure than the hexamer with 
ATPγS. It would appear that ATP binding induces global increases in secondary structure and 
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protection from solvent. This protection from solvent is likely due to decreases in local and global 
dynamics as increases in secondary structure rigidify the hexamer. This increase in rigidity can 
be thought of as a pre-payment of the entropic cost of substrate binding. This may have important 
implications for discrimination between soluble and aggregate substrates. When binding a large, 
stable aggregate, the main entropic penalty would come from decreases in mobility of the Hsp104 
hexamer. Conversely, when binding soluble, potentially properly folded substrates, the main 
entropic penalty would come from the substrate. This mechanism of rigidifying the hexamer in 
preparation for substrate binding could contribute to discriminating between aggregated 
substrates, and soluble proteins that could, but should not, be remodeled. We have shown 
through our XF data as well as FITC-casein binding assays that substrate binds in the NTD and 
NBD1 domains. In the rigid, low entropy state the NTD and NBD1 are poised for substrate 
binding and the MD is in a configuration where motif 2 is making interactions with the NTD and 
NBD1 while motif 1 is making repressive contacts with NBD2 [222]. As substrate binding occurs 
at the NTD and NBD1, and/or Hsp70 binds at the MD/NTD interface, a cascade of events is 
triggered which relieves inhibition and allows substrate remodeling to commence. Substrate 
binding may trigger ATP hydrolysis in NBD1, as is seen in ClpB [232], or it may occur randomly. 
Whichever the case, hydrolysis of ATP results in a loss of rigidity of helix 2 of the MD, which 
results in loss of the repressive MD-NBD2 contact [222]. This allows signal transmission between 
NTD/NBD1 and NBD2 and may coordinate cooperativity. Our XF data shows us that the 
nucleotide-binding sites in NBD2 are only partially filled in the hexamer with ATPγS, and some 
may be open and unoccupied (in contrast to the nucleotide binding sites in NBD1 which are either 
all full or closed in the hexamer with ADP). Upon initial ATP hydrolysis at NBD1 and relief of the 
MD-NBD2 repression, nucleotide binding may occur more robustly in NBD2. Nucleotide binding 
at NBD2 stimulates hydrolysis in NBD1 [140], and therefore fully activates the Hsp104 hexamer. 
As ATP is hydrolyzed, the secondary substrate-binding loop, which we identified in our XF study, 
becomes positioned to engage substrate, potentially to prevent diffusion. The channel of the 
Hsp104 hexamer collapses, making a peristaltic pump motion N- C-terminally (Chapter 2). 
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Substrate can be engaged in NBD2 as channel collapse and NBD1 loop movements pull 
substrate C-terminally. NBD1 exchanges ADP for ATP while the secondary substrate-binding 
loop prevents substrate diffusion, and the NTD and NBD1 reengage the substrate higher up. 
Once the hexamer has been engaged, iterative rounds of these actions results in remodeled 
substrates.  
 
3.3 Conclusions 
In this chapter we have identified, from XF oxidative modification data, 1) Regions in the 
NTD likely to be involved in substrate and Hsp70 binding, 2) Novel sites of NTD:NBD1:MD 
interaction which may mediate cooperativity of the hexamer for which the NTD is essential, 3) A 
loop in NBD1 that may engage substrate in the ADP bound state to prevent substrate diffusion as 
ADP is exchanged for ATP, 4) The region of the MD (helix 2) responsible and the mechanism of 
signal transmission between NBD1 and NBD2, 5) Confirmed the validity of a hexameric model of 
the NBD2 domain, 6) Proposed a comprehensive model for the mechanism of Hsp104 substrate 
remodeling, and 7) Identified regions and specific residues in all of the Hsp104 domains which 
may play important roles for the hexamer, allowing the field to make directed changes in Hsp104 
sequence rather than rely solely on random mutagenesis for the production of Hsp104 variants 
with altered activities. Our XF findings were supported using HD exchange (Alec Ricciuti, 
Englander lab), biochemical assays to confirm the importance of the NTD for substrate binding 
and productive Hsp70 interaction, in vivo and in vitro assays to confirm the importance of the 
novel NBD1 loop in substrate processing, and crosslinking studies to determine the MD:NBD2 
interaction[222] and the importance of hydrophobic residues in the hexamer interface. 
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Chapter 4: Conclusions and future directions 
 
4.1 Conclusions 
We have used a hybrid approach, applying several structural and biochemical 
techniques, to elucidate novel details of the structure of the Hsp104 hexamer and its mechanism 
of substrate remodeling. In Chapter 2, we set out to determine the role of the Hsp104 N-terminal 
domain (NTD) and to visualize large conformational changes of the hexamer using small and 
wide-angle x-ray scattering (SAXS/WAXS). In Chapter 3, we used an in solution technique, x-ray 
footprinting (XF), that directly probes the solvation state of the Hsp104 hexamer in the presence 
of different nucleotides. The changes in solvation allowed us to make predictions about what 
these conformational changes mean for the individual domains, the Hsp104 hexamer as a whole, 
and the mechanism of substrate remodeling. We complemented the XF data with biochemical 
techniques, and were able to elucidate novel insights into substrate binding and processing, 
interaction with Hsp70, movements of the coiled-coil middle domain, and the subunit:subunit 
interface. By combining data from throughout the thesis we were able to propose a model of how 
Hsp104 is activated and remodels substrate.  
In Chapter 2 we found that the Hsp104 NTD is necessary for nucleotide-dependent 
conformational changes that allow productive hexamer cooperativity. Cooperativity is dispensable 
for disordered aggregate dissolution, but necessary for robust and adaptable hexamer function 
[132]. This deficiency in hexamer cooperativity results in a deregulated ATPase rate, diminished 
unfoldase and tranlocase activity, and an inability to remodel exceptionally stable substrates such 
as amyloid, even in the presence of potentiating mutations. By examining the role of the N-
terminal domain, we also discovered details about the WT Hsp104 hexamer. From our 
SAXS/WAXS studies in Chapter 2 we found that the Hsp104 channel undergoes peristaltic pump-
like motions, which would facilitate directional movement of substrate through the central channel. 
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We have also discovered that partial unfolding of substrate can be sufficient for aggregate 
dissolution.  
In Chapter 3 we used XF data to determine changes in solvation between Hsp104 
hexamers bound to different nucleotides, and complemented our XF findings with biochemical 
assays. We found regions in the NTD likely to be involved in substrate and Hsp70 binding, and 
identified novel sites of NTD:NBD1:MD interaction, which may mediate cooperativity of the 
hexamer. We discovered a loop in NBD1 that may engage substrate in the ADP bound state to 
prevent substrate diffusion as ADP is exchanged for ATP. We determined the region of the MD 
(residues ~455-475 in helix 2) likely to be responsible for signal transmission between NBD1 and 
NBD2, and proposed a mechanism of transmission. We confirmed the validity of a hexameric 
model of the NBD2 domain we proposed based on published Hsp100 hexameric crystal 
structures. We proposed a comprehensive model for the mechanism of Hsp104 substrate 
remodeling and finally, we identified regions and specific residues in all of the Hsp104 domains 
that may play important roles for the hexamer. Identification of these regions will allow us to make 
directed changes in Hsp104 sequence rather than rely solely on random mutagenesis for 
production of Hsp104 variants with altered activities.  
By combining our findings we propose a comprehensive model of the mechanism of 
Hsp104 substrate remodeling (Figure 1). Our findings indicate that ATP binding induces global 
increases in secondary structure and protection from solvent. This protection from solvent is likely 
due to decreases in local and global dynamics as increases in secondary structure rigidify the 
hexamer. Since Hsp104 engages substrate in the ATP-bound state, the rigidity of the hexamer 
with ATP can be thought of as a pre-payment of the entropic cost of substrate binding, especially 
since the entropic cost of binding to a large, insoluble aggregate would be paid primarily by the 
Hsp104 hexamer. In the rigid, low entropy state the NTD and NBD1 are poised for substrate 
binding and the MD is in a configuration where motif 2 is making interactions with the NTD and 
NBD1 while motif 1 is making repressive contacts with NBD2. As substrate binding occurs at the  
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NTD and NBD1, or Hsp70 binds at the MD/NTD interface, or both, a cascade of events is 
triggered which relieves inhibition and allows substrate remodeling to commence. This step can 
be thought of as ‘priming the pump’, or allowing the hexamer to unleash its auto-inhibited 
remodeling activity. Substrate binding may trigger ATP hydrolysis in NBD1, as is seen in ClpB 
[232], or it may occur randomly. Whichever the case, hydrolysis of ATP results in a loss of rigidity 
of helix 2 of the MD, which results in loss of the repressive MD-NBD2 contact [222]. This allows 
signal transmission between NTD/NBD1 and NBD2 and may coordinate cooperativity. Our XF 
data shows us that the nucleotide-binding sites in NBD2 are only partially filled in the hexamer 
with ATPγS, and some may be open and unoccupied (in contrast to the nucleotide binding sites in 
NBD1 which are either all full or closed in the hexamer with ATPγS). Upon initial ATP hydrolysis 
at NBD1 and relief of the MD-NBD2 repression, nucleotide binding may occur more robustly in 
NBD2. Nucleotide binding at NBD2 stimulates hydrolysis in NBD1 [140], and therefore fully 
activates the Hsp104 hexamer. This positive feedback loop allows the hexamer to transition from 
a repressed state to an active state. As ATP is hydrolyzed, the secondary substrate-binding loop, 
which we identified in our XF study, becomes positioned to engage substrate, potentially to 
prevent diffusion. The channel of the Hsp104 hexamer collapses, further preventing substrate 
diffusion, and makes a peristaltic pump motion with a wave of constriction moving N- C-
terminally. Substrate can be engaged in NBD2 as channel collapse and NBD1 loop movements 
pull substrate C-terminally. NBD1 exchanges ADP for ATP and the NTD and NBD1 reengage the 
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substrate higher up. Once the hexamer has been engaged, iterative rounds of these actions 
results in remodeled substrates.  
 
4.2 Future directions 
Our XF studies have identified a number of regions that may be involved in substrate 
binding, Hsp70 interaction, hexamer cooperativity and signal transmission between domains. The 
next steps would be to test these areas to confirm or identify their role, and to make mutations to 
tailor Hsp104 to novel functions. In the NTD these regions include residues within the 
hydrophobic patch, which we believe may bind substrate, as well as regions that may be involved 
in Hsp70 interaction and an interface between the NTD, NBD1 and MD. Specifically, these 
residues include A91, L92, V95, and L96 (for the hydrophobic patch), T87, Y90, K94, S124, and 
S125 (for potential Hsp70 interaction site A) I102, Q103, K107 and S109 (for potential Hsp70 
interaction site C) and residues that may be involved in the NTD:NBD1:MD interface, 8-15 (NTD), 
39-52 (NTD), 148-166 (NTD-NBD1 linker), 230-240 (NBD1) and 496-498 (MD). Using 
mutagenesis and biochemical assays (substrate binding, aggregate reactivation, etc.) we can test 
whether these regions are involved in the activities we propose. The hydrophobic patch, if 
confirmed to be involved in substrate binding, could be mutated to develop Hsp104 variants with 
altered substrate specificities. Additionally, we have already identified potentiating mutations in 
the proposed NTD:NBD1:MD interface (D498V [179], T499D and I230N [Amber Tariq, Shorter lab 
unpublished data]), and therefore further mutations directed to these regions may reveal more 
potentiated Hsp104 variants with altered behaviors. We would also like to be able to test whether 
our proposed mechanism for the NBD1 291-GNGKD-295 loop, preventing substrate diffusion as 
subunits rebind ATP, is correct. We would like to measure release of substrate due to ATP 
hydrolysis after initial binding events, to confirm whether mutations in the loop result in more, or 
faster release of substrate. To do this we would incubate Hsp104 variants with ATPγS and FITC-
casein. Once the fluorescence polarization (FP) signal reaches equilibrium, we can add a large 
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excess of ADP. As ATPγS is exchanged for ADP, some amount of substrate will be released. By 
comparing the change in FP signal between WT Hsp104 and our loop variants, we will be able to 
determine if the loop plays a role in preventing substrate diffusion.  
Crosslinking studies and functional assays would further confirm the NBD2 hexameric 
model. If the model is sound, it can be used as a template for creation of a full hexameric model, 
with modifications to the original model based on the XF solvation data, particularly in the 
placement of the coiled-coil MD. This starting model can be used to generate ensembles of 
Hsp104 hexamers that can be filtered based on SAXS and XF constraints. These ensembles will 
allow us to visualize different possible orientations of highly mobile domains such as the MD and 
NTD.  
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Chapter 5: Methods 
 
5.1 Protein expression and purification  
Hsp104 variants were generated using QuikChange lightning mutagenesis (Agilent). 
Hsp104 variants were expressed and purified as N-terminally His6-tagged constructs in a 
modified pPROEX HTb vector as described [233] or as untagged constructs in a pNOTAG vector 
from the Lindquist lab. Briefly, expression of Hsp104 variants in BL21 RIL (His6-tagged 
constructs) or BL21 DE3 RIL (untagged constructs) was induced with 1 mM IPTG overnight at 
15°C once cells reached log phase. Cells were harvested via centrifugation (4,000 rpm, 4°C, 20 
min), resuspended in lysis buffer – 40 mM HEPES-KOH pH 7.4, 500 mM KCl, 20 mM MgCl2, 
2.5% (w/v) glycerol, 20 mM imidazole, 5 µM pepstatin A, complete protease inhibitor cocktail (1 
EDTA-free tablet/50 mL), and 2 mM β-mercaptoethanol for His6-tagged constructs or 50 mM Tris, 
pH 8, 10 mM MgCl2, 2.5% glycerol (w/v), 5 µM pepstatin A, complete protease inhibitor cocktail (1 
EDTA-free tablet/50 mL) (Roche), 2 mM β-mercaptoethanol for untagged constructs. Cells were 
lysed using a French press (Emulsiflex) homogenizer and cell debris removed via centrifugation 
(16,000 rpm, 4°C, 20 min). A 50% slurry of lysis buffer equilibrated Ni-Sepharose beads (GE) (for 
His6-tagged constructs, 2 mL beads per 1 L of cells) or Affi-Gel Blue Media resin (Bio-Rad) (for 
untagged constructs, 3 mL resin per 1 L of cells) was added to the supernatant. Samples were 
rotated at 20 rpm, 4°C for 3 hours (His6-tagged constructs) or 5 hours (untagged constructs). 
After incubation the beads/resin were washed three time, with 1) wash buffer – 40 mM HEPES-
KOH pH 7.4, 140 mM KCl, 10 mM MgCl2, 2.5% (w/v) glycerol, 20 mM imidazole, 2 mM β-
mercaptoethanol), 2) wash buffer with 1 M KCl, and 3) wash buffer (His6-tagged constructs), or 4 
times with 50 mM Tris, pH 8, 10 mM MgCl2, 100 mM KCl, 2.5% glycerol (w/v), 2 mM β-
mercaptoethanol (for untagged constructs). The beads/resin were collected after each wash by 
centrifugation at 2,000 rpm for 2 min at 4°C (Eppendorf 5810R centrifuge) and the supernatant 
discarded. After washing the protein was eluted with wash buffer with 350 mM imidazole (for His6-
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tagged constructs) or wash buffer with 1 M KCl (for untagged constructs). After elution His6-
tagged and untagged constructs were buffer exchanged into buffer Q (20 mM Tris-HCl pH 8, 0.5 
mM EDTA, 5 mM MgCl2, 50 mM NaCl) and purified via anion exchange using a Resource Q 
column (GE) and a gradient of buffer Q+ (20 mM Tris-HCl pH 8, 0.5 mM EDTA, 5 mM MgCl2, 1 M 
NaCl) Hsp104 typically elutes off the column at ~34% buffer Q+ (~31 mS/cm). All His6-tagged 
constructs contain a TEV protease cleavage site. Prior to use, the His6-tag was cleaved off with 
proTEV protease (Promega) or AcTEV protease (Invitrogen) according to manufacturer’s 
instructions. His6-tagged Sup35 was purified as described from BL21 (DE3) pLysS cells [20, 81].  
ClpP was expressed and purified as a C-terminally His6-tagged construct as described [179]. 
RepA1-70-GFP and GroELTRAP were purified as described [113]. Firefly luciferase was from Sigma. 
Hsc70, Hdj2, Hsp72 and Hsp40 were from Enzo Life Sciences, FITC-casein was from Sigma, and 
creatine kinase was from Roche. Unless otherwise stated Hsp104 concentrations refer to the 
hexamer.  
 
5.2 Sup35 fiber inhibition assay 
Amyloid fiber assembly of full length Sup35 was tracked by monitoring the change in 
fluorescence of the amyloid binding dye thioflavin T (excitation at 450 nm, emission 482 nm) on a 
Tecan Infinite M1000 [20, 81]. The assembly reactions were carried out in buffer alone (40 mM 
HEPES 7.4, 15 0mM KCl, 20 mM MgCl2, 10% w/v glycerol, 1 mM GTP, 1 mM DTT, 5.1 mM ATP 
and an ATP regenerating system (1 mM creatine phosphate, 0.25 µM creatine kinase) or buffer 
with an Hsp104 variant. Reaction endpoints were also visualized by negative stain electron 
microscopy [20, 81]. 
 
5.3 Luciferase reactivation 
Luciferase aggregation and reactivation were performed as described [132]. Briefly, firefly  
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luciferase (50 µM) was incubated in LRB (25 mM HEPES-KOH pH 7.4, 150 mM KOAc, 10 mM 
MgOAc, 10 mM DTT) with 8 M urea at 30°C for 30 min to form aggregates. After a rapid 100-fold 
dilution in LRB, the aggregates were flash frozen and stored at -80°C until use. Reactivation 
assays were carried out with Hsp104 (1 µM), Hsp70 (Hsc70 or Hsp72 at 1 µM), Hsp40 (Hdj2, 1 
µM), 5.1mM ATP, and an ATP regenerating system (1mM creatine phosphate, 0.25 µM creatine 
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kinase) for 90 min at 25°C. Alternatively, Hsp70, Hsp40 and 5.1 mM ATP were replaced with 5.1 
mM nucleotide of different ratios of ATP:ATPγS. Luciferase activity was assessed using a 
luciferase assay system from Promega. Luminescence was measured on a Tecan Infinite M1000 
or Safire2 plate reader.  
 
5.4 In vivo thermotolerance assay (Michelle Go, Shorter lab) 
Yeast thermotolerance assays were performed as described [179]. Briefly, W303 
Δhsp104 (MATa, can1-100, his3-11,15, leu2-3,112, trp1-1, ura3-1, ade2-1, hsp104:kanMX4) 
yeast was transformed with a centromeric pHSE plasmid encoding an Hsp104 variant [106]. The 
strains were grown in SD-ura media to an OD600 of 0.5, and incubated at 37°C for 30 min to 
induce Hsp104 expression. Cells were then heat shocked for 0-20 min at 50°C, immediately 
transferred to ice for 2 min, and then spotted on SD-ura plates in a 5–fold dilution series. After a 
two-day incubation at 30°C, plates were imaged for analysis. Alternatively, the thermotolerance 
products were plated on SD-ura plates, and after a 2-day incubation at 30°C colonies were 
counted using an acolyte automated colony counter (Synbiosis). Immunoblotting was used to 
confirm expressions levels of Hsp104 and disease proteins (when applicable). 
 
5.5 Testing toxicity suppression of human disease proteins (Dr. Meredith Jackrel, 
Shorter lab) 
Full length or NTD deletion Hsp104 variants harboring known potentiating mutations were 
transformed into yeast with pAG303GAL-TDP-43, pAG303GAL-FUS, or pAG303GAL-α-syn. The 
strains were then spotted in 5-fold dilution series on glucose (off) or galactose (on) media to test 
for toxicity suppression [179]. 
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5.6 ATPase assay 
Hsp104 variants (0.25 µM monomer) were incubated for 5 min at 25°C with ATP (1 mM). 
ATPase activity was assessed using a malachite green phosphate detection kit (Innova). 
 
5.7 Fluorescence polarization 
Fluorescent polarization experiments with Hsp104 variants and FITC-casein were 
performed as described [179]. Briefly, Hsp104 variants in increasing concentrations (10 nM-4 µM) 
were added to FITC-casein (6 nM), and ATPγS (2 mM) in LRB. After a 20 min incubation 
fluorescent polarization of the FITC-casein was measured using a Tecan Infinite M1000 plate 
reader. For binding in the presence of ADP, ATPγS was replaced with 2 mM ADP, FITC-casein 
was 100 nM and Hsp104 concentrations varied from 0.5-15 µM.  
 
5.8 Casein degradation 
FITC-casein degradation assays were performed as described [179]. Briefly, FITC-casein 
(100 nM-60 µM) was incubated with HAP variants (1 µM), ClpP (21 µM monomer), 5.1 mM ATP 
and an ATP regenerating system. Degradation of FITC-casein was monitored by measuring 
fluorescence of free FITC (excitation 490 nm, emission 520 nm) using a Tecan Infinite M1000 or 
Safire2 plate reader. 
 
5.9 RepA1-70-GFP unfolding 
RepA1-70-GFP assays were performed as described [179]. Briefly, RepA1-70-GFP (0.7 µM) 
was added to GroELTRAP (1.5 µM), WT or ΔN Hsp104 (1 µM), either 2.6 mM ATP and 2.5 mM 
ATPγS (1:1) or 3.43 mM ATP and 1.67 mM ATPγS (2:1), BSA (0.02 mg/mL), Triton (0.005%) and 
an ATP regenerating system (1 mM creatine phosphate, 0.25 µM creatine kinase). The decrease  
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in fluorescence (excitation at 395 nm, emission 510 nm) over time was monitored using a Tecan 
Infinite M1000.  
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5.10 Mutant subunit doping 
Luciferase aggregation and reactivation were performed as described [132] (see above). 
Reactivation assays were carried out with Hsp104 (1 µM), Hsp72 (1 µM), Hdj2 (1 µM), 5.1 mM 
ATP, and an ATP regenerating system (1 mM creatine phosphate, 0.25 mM creatine kinase) for 
90 min at 25°C. Prior to addition, WT (or ΔN) Hsp104 and mutant were mixed in the following 
ratios: 6:0, 5:1, 4:2, 3:3, 2:4, 1:5, 0:6 and incubated for 30 min on ice. Luciferase activity was 
assessed using a luciferase assay system from Promega. Luminescence was measured on a 
Tecan Infinite M1000.  
 
5.11 Glutaraldehyde crosslinking 
 Glutaraldehyde crosslinking experiments were carried out as described [139]. Briefly, 
Hsp104 variants were diluted to 0.04 mg/mL in 40 mM Hepes-KOH pH 7.4, 140 mM KCl, 10 mM 
MgCl2, 1 mM DTT plus either 20 mM EDTA or 5 mM ATP. The samples were incubated with 
glutaraldehyde (0.1%) for 12 min. The crosslinking reaction was quenched by addition of 1 M 
glycine pH 6, and the proteins were precipitated using trichloroacetic acid. After two washes with 
chilled acetone the samples were run on an SDS-PAGE gel and reactions products visualized 
using a silver stain kit (Invitrogen). 
 
5.12 Synchrotron hydroxyl radical footprinting (XF) 
5.12.1 Sample irradiation 
WT Hsp104 was purified as in [233], with a final step of gel filtration using a Superdex 
200 column (GE) equilibrated in 50 mM Cacodylate pH 7.0, 140 mM KCl, 10 mM MgCl2, (for the 
hexamer) or 50 mM Cacodylate pH 7.0, 500 mM KCl, and 20 mM MgCl2 (for the monomer, as 
confirmed by Size Exclusion Chromatography followed by Multi Angle Light Scattering, SEC-
MALS (Wyatt)). Samples were kept on ice and transported to Brookhaven National Laboratory 
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(Upton, NY). All samples were kept on ice and diluted at the beamline 10 min prior to use to 10 
µM Hsp104 in 50 mM Cacodylate pH 7.0, 140 mM KCl, 10 mM MgCl2, and 1 mM ADP or ATPγS 
(for the hexamer) or 50 mM Cacodylate pH 7.0, 500 mM KCl, and 20 mM MgCl2 (for the 
monomer). X-ray dose- dependent oxidation of Alexa488 (Invitrogen) in the three buffer 
conditions was used to determine optimal exposure times and provide normalization constants. 
The samples were exposed to a mirror-focused synchrotron x-ray beam (5.5 mrad angle, focus 
value of 6 mm) at the X28C beamline of the National Synchrotron Light Source at Brookhaven 
National Laboratory for 0-20 ms. The exposure time of the samples was controlled by flow rate 
through the flow cell of a KinTek (Austin, TX) stopped flow apparatus [218]. Oxidation was 
immediately quenched by the addition of 10 mM methioninamide, and samples were frozen with 
dry ice, transported to the University of Pennsylvania and stored at -80°C. 
 
5.12.2 Mass spectrometry on the XF samples 
The irradiated samples were thawed on ice and diluted to 1 µM in 5mM HEPES NaOH 
pH 7.0, 140 mM KCl, 10 mM MgCl2, 1 mM DTT, 1% TFA and immediately injected onto an in-line 
fragmentation-separation/MS analysis system. Samples first passed through an immobilized 
pepsin column onto a C8 trap column and washed for 3 min (2% acetonitrile, 1% formic acid, pH 
2, 0°C). Samples then flowed onto an analytical C18 column, were eluted using a gradient 
optimized for the highly charged Hsp104 peptides (6 µL/min non-linear 2-50% acetonitrile 
gradient, 0.1% formic acid, pH 2 and 0°C), and injected by electron spray ionization into an LTQ 
Orbitrap XL mass spectrometer (Thermo Scientific). The four most abundant peptides from each 
scan was selected for fragmentation by CID and measured in the LTQ stage.  
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5.12.3 Identification of oxidatively modified peptides using ExMS-CL (Dr. Zhong-yuan 
Kan, Englander lab) 
A modified version of the ExMS program, called ExMS-CL (which stands for “covalent 
labeling”), was used to process/analyze the x-ray footprinting MS/MS data to identifying oxidative 
modifications on the protein samples. Its workflow can be briefly described as follows. First, 
ExMS-CL makes a peptide list of the target protein including unmodified and modified peptides. 
The unmodified peptides are obtained from searching MS/MS runs (similar to SEQUEST), with a 
user-set score threshold (in this case a p score cut-off of 0.01) to build a “peptide pool”. Based on 
the sequence of the unmodified “peptide pool” and the table of amino acid specific potential 
oxidative modifications (see Table 1 in ref [213]), ExMS-CL enumerates a full list of peptides with 
all potential modifications. For each peptide in the list, its theoretical monoisotopic m/z and 
isotopic peak intensity distribution (the envelope shape) are calculated. The reference retention 
time (RT) of unmodified peptides is directly copied from the MS/MS search result, and ExMS-CL 
uses a user-set shift (e.g., -3 minutes to +5 minutes) to create and use a specific RT search 
window for modified version of peptides. All of this information is saved together in the peptide 
list.    
By using the above compiled list, ExMS-CL searches each peptide in the MS1 data, 
within each specific RT window for modified versions of peptides (see Figure 4 for an example of 
unmodified and modified versions of a peptide identified by ExMS-CL). ExMS-CL matches 
peptide theoretical masses and envelope shapes to the experimental data, and performs multiple 
tests and checks as in the original ExMS (algorithm details described in ref [220]) to ensure the 
identification is correct. At the end of this step, normal ExMS outputs are saved, including every 
identified peptides RT range, summed isotopic peak mass spectrum and centroid. Next, ExMS-
CL confirms the modified peptides and locates the modification sites at MS1 and MS2 levels. 
From the MS1 ExMS output, peptide (“goodModPepSet”) and protein sequence (“proModTable”) 
tables are compiled to list all the modifications found with their individual position on the peptide, 
the peptide intensity quantification, and the number of modification possibilities (“sharing times”).  
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The latter information can be used to judge if the modification can be uniquely assigned to an 
amino acid location. Further, ExMS-CL looks into the MS2 data by matching the parent ions to 
the mass of found modified peptides, then extracting the matched experimental CID spectra and 
comparing with the peptide’s predicted CID spectra. A MS2 score is calculated to help confirm the 
identity of that modified peptide. Finally, ExMS-CL reports the analysis results of identified 
peptides in both modified and unmodified forms. 
 
5.12.4 Analysis of modification rate of identified peptides using Matlab (Dr. Matthew 
Sochor, Lewis lab) 
Output of ExMS-CL was read into Matlab (Mathworks) and analyzed using custom 
scripts. Modified and unmodified versions of peptides and their intensities were read from the 
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ExMS-CL output files and matched up. Fraction unmodified was calculated for each MS/MS 
sample using the peptide intensities (the sum of unmodified versions of the peptide divided by the 
sum of all modified and unmodified versions of the peptide). For each timepoint, the MS/MS run 
outputs were averaged together and standard deviation calculated. For each peptide, the average 
fraction unmodified was reported for each timepoint. Once time-dependent modification was 
calculated, each peptide was binned into one of three categories by the Matlab program, no time-
dependent modification (0-1 timepoints after time 0 were modified with respect to time 0), 
sporadic modification (2 timepoints after time 0 were modified with respect to time 0), and time-
dependent modification (greater than 2 timepoints after time 0 were modified with respect to time 
0). For the peptides that displayed time-dependent modification, the program used the first four 
timepoints (0, 2.5, 5, and 7.5 ms) to determine the rate of modification by fitting to a first order 
exponential decay. The earliest timepoints were used due to evidence of over-oxidation in many 
of the 10 and 20 ms timepoints. Each of the fits was visually checked and manually refitting using 
Origin 8.1 was used when the Matlab program failed to converge onto a visually accurate fit to the 
data.  
 
5.13 Small and wide angle x-ray scattering (SAXS/WAXS) 
5.13.1 SAXS methods overview 
X-ray scattering data were collected at beamline 4-2 at the Stanford Synchrotron 
Radiation Laboratory (SSRL, Menlo Park, CA), and beamline X9 at the National Synchrotron 
Light Source (NSLS, Upton, NY) (details specific to each beamline below). Data were collected at 
multiple concentrations between 1.5 mg/mL and 6.0 mg/mL. The two-dimensional scattering 
images were collected on CCD detectors, and circularly averaged using software developed at 
the individual beamlines to yield one-dimensional scattering profiles as a function of momentum 
transfer q (q=4πsin(θ)/λ, where 2π is the scattering angle and λ is the wavelength. The raw 
scattering data were scaled and buffer subtracted using the program PRIMUS [234]. Each 
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individual scattering curve was visually inspected for radiation damage and aggregation prior to 
averaging, including Guinier and Kratky plot analysis. For data collected at NSLS, where both 
SAXS and WAXS data are collected on separate detectors simultaneously, averaged scattering 
curves from the SAXS and WAXS detectors were scaled and merged in PRIMUS to yield a low-
noise composite curve. The radii of gyration (Rg) were initially calculated using Guinier plots 
[235]. Distance distribution functions P(r) were calculated by the program GNOM [236] using an 
indirect Fourier transform. The maximum dimension of the particle (Dmax) was determined by 
examining the quality of fit to the experimental data for a Dmax range of 180 Å to 280 Å, varied in 5 
Å. Fits were assessed by maximizing the Total Estimate figure, minimizing the discrepancy 
between calculated and experimental profiles, and optimizing the visual properties of the shape 
distribution function. Values for Rg were computed from the second moment of the P(r) and 
compared favorably to those calculated using Guinier plot analysis. The Porod volume and P 
value were calculated by the java-based program ScÅtter: http://www.bioisis.net/tutorial/9. The 
mass of the particle was calculated from Qr as described [237]. 
 
5.13.2 Small-Angle X-ray Scattering at SSRL Beamline 4-2 
SAXS data were collected at beamline 4-2 at the Stanford Synchrotron Radiation 
Laboratory (SSRL, Menlo Park, CA) at room temperature with a sample to detector distance of 
1600 mm. Using software developed at the beamline, two-dimensional scattering profiles 
collected using a Rayonix MX225-HE detector were converted into one-dimensional intensity 
profiles. The x-ray wavelength was 1.2 Å and the angular range was 0.0140 ≤ q ≥ 0.4435 Å-1. The 
protein samples and matching buffer solutions, 30 µL for each measurement, were exposed for 
ten 10 s exposures in a 1.2 mm path capillary with thin mica windows sealed across the 
evacuated flight path. Each exposure was checked for radiation damage by the automated 
software prior to averaging. After each measurement the capillary was washed thoroughly and 
purged with compressed nitrogen. 
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5.13.3 Small and Wide-Angle X-ray Scattering at NSLS Beamline X9  
SAXS and WAXS data were collected simultaneously at beamline X9 at the National 
Synchrotron Light Source (NSLS, Upton, NY) at 10°C, or 25°C for the ADP-AlFx state, by two 
overlapping detectors, a Mar 165 CCD SAXS detector 3.4 m from the sample, and a custom built 
Photonic Science CCD WAXS detector. The two-dimensional images were converted into one-
dimensional scattering profiles using software developed at the beamline. The x-ray wavelength 
was 0.855 Å and the angular range collected was 0.00550 ≤ q ≥ 1.0060; an angular range of 
0.0100 ≤ q ≥ 0.7950 was used for data analysis and reconstructions; reconstructions were also 
carried out with q=0.4950, which compared favorably to the reconstructions to q=0.7950. The 
sample cell contained a glass capillary sealed across the evacuated chamber. The protein 
samples and matching buffer solutions were flowed through the capillary and oscillated during 
exposure to reduce radiation damage. For data collection 30 µL of the protein sample or 
matching buffer solution was exposed for 180 s, subdivided into 3 60 s exposures of 10 µL.  
 
5.13.4 Shape reconstructions from SAXS/WAXS data 
Shape reconstructions of the hexamer were generated using the program GASBOR 
[201]. Information required for GASBOR modeling is the x-ray scattering profile, the number of 
residues to be modeled (GASBOR assigns a dummy reside to represent each residue), and the 
Dmax. Six-fold symmetry was imposed. Since each inverse scattering has no one unique solution, 
ten independent ab initio reconstructions were performed for each state. Regions that are flexible 
are assigned different positions in individual simulations. The ten independent dummy residue 
reconstructions were aligned and scored based on the normalized spatial discrepancy (NSD) 
[238]. The individual reconstructions were only included if their NSD < mean NSD + 2 * variation. 
The included reconstructions were averaged and filtered to yield a final most-probable model 
using the DAMAVER suite of programs [202]. The individual bead models were visualized in 
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PyMOL (DeLano, W.L. The PyMOL Molecular Graphics System (2002) on World Wide Web 
http://www.pymol.org). The filtered and unfiltered average models were converted to volume 
envelopes using SITUS [239] and visualized using Chimera [240]. 
 
5.13.5 Channel calculations (Dr. Matthew Sochor, Lewis lab) 
5.13.5.1 Volume measurement  
The situs maps were converted to mrc maps using map2map, part of the SITUS suite of 
programs [239]. The three-dimensional electron density file in the .mrc format was imported into 
Matlab (Mathworks) using a custom script which parses the file into a three dimensional matrix of 
electron density. The read function also extracts the voxel dimensions in order to scale the 
measurement. The built in Matlab function “edge” was used to find the edges of two-dimensional 
slices of the electron density using the Sobel method. The Sobel method finds the edges by 
approximating the first derivative over the image; maxima of the first derivative are edges.   
A custom script was then used to find edges for each two-dimensional slice of the density 
matrix. The x, y, and z coordinates of each edge point were stored in an array and the array 
scaled by the voxel dimensions. This array is a list of all three-dimensional vectors; each vector 
points to a unique edge point. The built in Matlab function “convhulln” was then used to convert 
this vector array into a convex hull and it measured the volume of the hull. The convex hull is the 
shell of the channel and the volume is the volume of the Hsp104 hexamer channel. 
 
5.13.5.2 Distance measurement 
Distance was measured for each slice of the channel. First, edges were found for each 
slice using the Matlab function “edge”. A horizontal mid-line of the channel was extracted and the 
distance from edge to edge was measured, scaled by the horizontal voxel dimension. The vertical 
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mid-line of the channel was then extracted and the edge-to-edge scaled distance was measured. 
Both distances were stored in an array. Then the slice was rotated 5 degrees and the algorithm 
was repeated to measure horizontal and vertical edge-to-edge, scaled distances. When the 
image had been rotated 45 degrees, every distance across the channel had been measured for a 
total of 18 distance measurements. The algorithm was then iterated over every slice of the 
density to measure the channel widths for each slice. The final array of distances was then output 
for further processing. 
 
5.14 Hydrogen – deuterium exchange (Alec Ricciuti, Englander lab) 
 Hydrogen-deuterium exchange was carried out as described [220, 241] on the monomer, 
apo hexamer, hexamer with ADP and hexamer with ATPγS at several deuterium exchange 
timepoints. Curves showing deuterium incorporation versus time for peptides from different 
samples allowed for the determination of protection factors for the hexameric states when 
compared to the monomer.  
 
5.15 Homology modeling 
Hsp104 was homology modeled domain by domain using SWISS-MODEL [242-244] 
based on the ClpB crystal structures 1khy (N terminal domain) [142] and 1qvr (NBD1, MD, NBD2) 
[102]. Hydrogen-exchange (HD) experiments have revealed that the Hsp104 monomer homology 
modeled off the tClpB structure has accurately placed loops and stable secondary structure (data 
not shown, Alec Ricciuti and Walter Englander, manuscript in preparation), suggesting that the 
homology model is reasonably accurate. The separate domains were then rigid body fit into the 
volume envelope for the hexamer with ATP generated by the SAXS analysis using Chimera 
[240].  
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